ga

Skip to content

My Files [0]

These are the files you have added to your collection.

  • You don't have any documents yet, feel free to browse the website and add documents.
Top

Search CDR Drug Database

Results 1 - 373 of 373
  1. Abacavir / lamivudine

    Brand name Kivexa
    Manufacturer GlaxoSmithKline
    Indication(s) HIV infection
    Submission type Initial
    Project Number S0038
    Date submission received 2005-07-26
    Status Complete
    Date recommendation issued 2005-12-07
    Recommendation List in a similar manner to other drugs in class

    Submission status report

    Recommendation and reasons

  2. Abatacept

    Brand name Orencia
    Manufacturer Bristol-Myers Squibb Canada
    Indication(s) Arthritis, Rheumatoid
    Submission type Pre-NOC
    Project Number SR0299
    Date submission received 2012-11-29
    Call for patient input 2012-11-23
    Patient input deadline 2012-12-21
    Status Complete
    Date recommendation issued 2013-07-18
    Recommendation List with criteria/condition

    Submission status report

    Recommendation and reasons

  3. Abatacept

    Brand name Orencia
    Manufacturer Bristol-Myers Squibb Canada
    Indication(s) Arthritis, Rheumatoid
    Submission type Resubmission #1
    Project Number S0187
    Date submission received 2009-12-02
    Status Complete
    Date recommendation issued 2010-06-17
    Recommendation List in a similar manner

    Submission status report

    Recommendation and reasons

  4. Abatacept

    Brand name Orencia
    Manufacturer Bristol-Myers Squibb Canada
    Indication(s) Arthritis, Juvenile Idiopathic & Juvenile Rheumatoid
    Submission type New Indication
    Project Number S0145
    Date submission received 2008-08-29
    Status Complete
    Date recommendation issued 2009-04-22
    Recommendation List with criteria/condition

    Submission status report

    Recommendation and reasons

  5. Abatacept

    Brand name Orencia
    Manufacturer Bristol-Myers Squibb Canada
    Indication(s) Arthritis, Rheumatoid
    Submission type Initial
    Project Number S0084
    Date submission received 2006-10-26
    Status Complete
    Date recommendation issued 2007-06-27
    Recommendation List with criteria/condition

    Submission status report

    Recommendation and reasons

  6. Acamprosate calcium

    Brand name Campral
    Manufacturer Prempharm Inc.
    Indication(s) Alcohol Abstinence
    Submission type Request for Advice
    Project Number S0143
    Date submission received 2008-07-22
    Status Complete
    Recommendation

    Submission status report

  7. Acamprosate calcium

    Brand name Campral
    Manufacturer Prempharm Inc.
    Indication(s) Alcohol Abstinence
    Submission type Initial
    Project Number S0108
    Date submission received 2007-08-29
    Status Complete
    Date recommendation issued 2008-03-27
    Recommendation List with criteria/condition
    Plain language recommendation Plain language recommendation
    Summary of CEDAC Discussion Summary of CEDAC Discussion
    Overview of CDR reports Overview of CDR reports

    Submission status report

    Recommendation and reasons

  8. Aclidinium bromide

    Brand name Tudorza Genuair
    Manufacturer Almirall Canada Ltd.
    Indication(s) Chronic Obstructive Pulmonary Disease (COPD)
    Submission type Initial
    Project Number SR0346
    Date submission received 2013-08-21
    Call for patient input 2013-07-30
    Patient input deadline 2013-09-13
    Status Active
    Date recommendation issued 2014-04-21
    Recommendation List with clinical criteria and/or conditions

    Submission status report

    Recommendation and reasons

  9. Adalimumab

    Brand name Humira
    Manufacturer AbbVie
    Indication(s) Ulcerative colitis
    Submission type New Indication
    Project Number SR0365
    Date submission received 2013-12-23
    Call for patient input 2014-07-09
    Patient input deadline 2014-08-28
    Status Active
    Recommendation

    Submission status report

  10. Adalimumab

    Brand name Humira
    Manufacturer AbbVie Corporation
    Indication(s) Arthritis, Juvenile Idiopathic
    Submission type New Indication
    Project Number SR0308
    Date submission received 2013-02-04
    Call for patient input 2013-01-04
    Patient input deadline 2013-02-22
    Status Complete
    Date recommendation issued 2013-07-18
    Recommendation List with criteria/condition

    Submission status report

    Recommendation and reasons

  11. Adalimumab

    Brand name Humira
    Manufacturer Abbott Laboratories, Limited
    Indication(s) Psoriasis
    Submission type New Indication
    Project Number S0130
    Date submission received 2008-04-15
    Status Complete
    Date recommendation issued 2008-10-16
    Recommendation List with criteria/condition

    Submission status report

    Recommendation and reasons

  12. Adalimumab

    Brand name Humira
    Manufacturer Abbott Laboratories, Limited
    Indication(s) Crohn's disease
    Submission type Resubmission #3
    Project Number S0105
    Date submission received 2007-07-12
    Status Complete
    Date recommendation issued 2007-12-19
    Recommendation List with criteria/condition
    Plain language recommendation Plain language recommendation
    Summary of CEDAC Discussion Summary of CEDAC Discussion
    Overview of CDR reports Overview of CDR reports

    Submission status report

    Recommendation and reasons

  13. Adalimumab

    Brand name Humira
    Manufacturer Abbott Laboratories, Limited
    Indication(s) Ankylosing spondylitis (AS)
    Submission type Resubmission #2
    Project Number S0087
    Date submission received 2006-11-17
    Status Complete
    Date recommendation issued 2007-06-27
    Recommendation List with criteria/condition

    Submission status report

    Recommendation and reasons

  14. Adalimumab

    Brand name Humira
    Manufacturer Abbott Laboratories Limited
    Indication(s) Arthritis, Psoriatic
    Submission type Resubmission #1
    Project Number S0066
    Date submission received 2006-06-21
    Status Complete
    Date recommendation issued 2006-11-29
    Recommendation List with criteria/condition

    Submission status report

    Recommendation and reasons

  15. Adalimumab

    Brand name Humira
    Manufacturer Abbott Laboratories Limited
    Indication(s) Arthritis, Rheumatoid
    Submission type Initial
    Project Number S0022
    Date submission received 2004-09-24
    Status Complete
    Date recommendation issued 2005-02-11
    Recommendation List with criteria/condition

    Submission status report

    Recommendation and reasons

  16. Adefovir dipivoxil

    Brand name Hepsera
    Manufacturer gilead Sciences Canada Inc.
    Indication(s) Hepatitis B
    Submission type Request for Advice
    Project Number S0103
    Date submission received 2007-06-29
    Status Complete
    Date recommendation issued 2007-10-18
    Recommendation List with criteria/condition

    Submission status report

    Recommendation and reasons

  17. Adefovir dipivoxil

    Brand name Hepsera
    Manufacturer Gilead Sciences Canada Inc.
    Indication(s) Hepatitis B
    Submission type Initial
    Project Number S0060
    Date submission received 2006-04-24
    Status Complete
    Date recommendation issued 2006-11-29
    Recommendation Do not list

    Submission status report

    Recommendation and reasons

  18. Aflibercept

    Brand name Eylea
    Manufacturer Bayer Inc.
    Indication(s) Macular edema secondary to central retinal vein occlusion
    Submission type New Indication
    Project Number SR0401-000
    Date submission received 2014-10-17
    Call for patient input 2014-08-19
    Patient input deadline 2014-10-08
    Status Active
    Recommendation

    Submission status report

  19. Aflibercept

    Brand name Eylea
    Manufacturer Bayer Inc.
    Indication(s) Macular edema, diabetic
    Submission type New Indication
    Project Number SR0396
    Date submission received 2014-09-16
    Call for patient input 2014-08-19
    Patient input deadline 2014-10-08
    Status Active
    Recommendation

    Submission status report

  20. Aflibercept

    Brand name Eylea
    Manufacturer Bayer Canada Inc.
    Indication(s) Macular degeneration, age-related
    Submission type Initial
    Project Number SR0361-000
    Date submission received 2013-11-18
    Call for patient input 2014-04-03
    Patient input deadline 2014-05-26
    Status Active
    Date recommendation issued 2014-10-20
    Recommendation List with clinical criteria and/or conditions

    Submission status report

    Recommendation and reasons

  21. Agalsidase alfa

    Brand name Replagal
    Manufacturer Transkaryotic Therapies Inc.
    Indication(s) Fabry Disease
    Submission type Initial
    Project Number S0006
    Date submission received 2004-02-19
    Status Complete
    Date recommendation issued 2004-11-24
    Recommendation Do not list

    Submission status report

    Recommendation and reasons

  22. Agalsidase beta

    Brand name Fabrazyme
    Manufacturer Genzyme Canada
    Indication(s) Fabry Disease
    Submission type Resubmission #1
    Project Number S0028
    Date submission received 2004-12-10
    Status Complete
    Date recommendation issued 2005-05-18
    Recommendation Do not list

    Submission status report

    Recommendation and reasons

  23. Agalsidase beta

    Brand name Fabrazyme
    Manufacturer Genzyme Canada
    Indication(s) Fabry Disease
    Submission type Initial
    Project Number S0007
    Date submission received 2004-02-24
    Status Complete
    Date recommendation issued 2004-11-24
    Recommendation Do not list

    Submission status report

    Recommendation and reasons

  24. Alefacept

    Brand name Amevive
    Manufacturer Biogen Idec Canada Inc.
    Indication(s) Psoriasis, moderate to severe chronic plaque
    Submission type Resubmission #1
    Project Number S0053
    Date submission received 2006-02-28
    Status Complete
    Date recommendation issued 2006-09-27
    Recommendation Do not list

    Submission status report

    Recommendation and reasons

  25. Alefacept

    Brand name Amevive
    Manufacturer Biogen Idec Canada Inc.
    Indication(s) Psoriasis, moderate to severe chronic plaque
    Submission type Initial
    Project Number S0024
    Date submission received 2004-11-16
    Status Complete
    Date recommendation issued 2005-05-26
    Recommendation Do not list

    Submission status report

    Recommendation and reasons

  26. Alemtuzumab

    Brand name Lemtrada
    Manufacturer Genzyme Canada, a Division of Sanofi-Aventis Canada Inc.
    Indication(s) relapsing remitting multiple sclerosis
    Submission type Initial
    Project Number SR0405-000
    Date submission received 2014-11-27
    Call for patient input 2014-10-14
    Patient input deadline 2014-12-02
    Status Queued
    Recommendation

    Submission status report

  27. Alemtuzumab

    Brand name Lemtrada
    Manufacturer Genzyme Canada, a Division of sanofi-aventis Canada Inc.
    Indication(s) Multiple Sclerosis, relapsing
    Submission type Pre-NOC
    Project Number SR0355
    Date submission received 2013-10-01
    Call for patient input 2013-09-30
    Patient input deadline 2013-10-23
    Status Withdrawn
    Recommendation

    Submission status report

  28. Alendronate sodium / cholecalciferol

    Brand name Fosavance 70/5600
    Manufacturer Merck Frosst Canda Ltd.
    Indication(s) Osteoporosis
    Submission type Initial
    Project Number S0153
    Date submission received 2008-12-18
    Status Complete
    Date recommendation issued 2009-06-17
    Recommendation List in a similar manner to other drugs in class

    Submission status report

    Recommendation and reasons

  29. Alendronate sodium / cholecalciferol

    Brand name Fosavance
    Manufacturer Merck Frosst Canda Ltd.
    Indication(s) Osteoporosis
    Submission type Initial
    Project Number S0059
    Date submission received 2006-03-27
    Status Complete
    Date recommendation issued 2006-09-27
    Recommendation Do not list

    Submission status report

    Recommendation and reasons

  30. Alglucosidase

    Brand name Myozyme
    Manufacturer Genzyme Canada Inc.
    Indication(s) Pompe’s disease
    Submission type Initial
    Project Number S0080
    Date submission received 2006-10-10
    Status Complete
    Date recommendation issued 2007-06-14
    Recommendation List with criteria/condition

    Submission status report

    Recommendation and reasons

  31. Aliskiren

    Brand name Rasilez
    Manufacturer Novartis Pharmaceuticals Canada Inc.
    Indication(s) Hypertension
    Submission type Initial
    Project Number S0118
    Date submission received 2007-11-30
    Status Complete
    Date recommendation issued 2008-06-25
    Recommendation Do not list

    Submission status report

    Recommendation and reasons

  32. Alitretinoin

    Brand name Toctino
    Manufacturer Actelion
    Indication(s) Eczema
    Submission type Initial
    Project Number S0232
    Date submission received 2011-05-06
    Call for patient input 2011-05-09
    Patient input deadline 2011-05-30
    Status Complete
    Date recommendation issued 2011-10-24
    Recommendation List with criteria/condition
    Plain language recommendation Plain language recommendation

    Submission status report

    Recommendation and reasons

  33. Almotriptan

    Brand name Axert
    Manufacturer Janssen-Ortho Inc.
    Indication(s) Migraine
    Submission type Initial
    Project Number S0005
    Date submission received 2003-12-24
    Status Complete
    Date recommendation issued 2004-05-27
    Recommendation List in a similar manner to other drugs in class

    Submission status report

    Recommendation and reasons

  34. Alogliptin

    Brand name Nesina
    Manufacturer Takeda Canada Inc.
    Indication(s) Diabetes mellitus (Type 2)
    Submission type Initial
    Project Number SR0368-000
    Date submission received 2014-01-30
    Call for patient input 2014-07-09
    Patient input deadline 2014-08-28
    Status Active
    Recommendation

    Submission status report

  35. Alogliptin plus metformin

    Brand name Kazano
    Manufacturer Takeda Canada Inc.
    Indication(s) Diabetes mellitus (Type 2)
    Submission type Initial
    Project Number SR0367-000
    Date submission received 2014-01-30
    Call for patient input 2014-07-09
    Patient input deadline 2014-08-28
    Status Active
    Recommendation

    Submission status report

  36. Ambrisentan

    Brand name Volibris
    Manufacturer GlaxoSmithKline Inc.
    Indication(s) Pulmonary arterial hypertension (WHO class II and III)
    Submission type Initial
    Project Number S0142
    Date submission received 2008-07-09
    Status Complete
    Date recommendation issued 2008-12-17
    Recommendation List with criteria/condition

    Submission status report

    Recommendation and reasons

  37. Amlodipine besylate / atorvastatin calcium

    Brand name Caduet
    Manufacturer Pfizer Canada Inc.
    Indication(s) Hypertension/ Dyslipidemia
    Submission type Initial
    Project Number S0048
    Date submission received 2005-12-15
    Status Complete
    Date recommendation issued 2006-05-17
    Recommendation List with criteria/condition

    Submission status report

    Recommendation and reasons

  38. Apixaban

    Brand name Eliquis
    Manufacturer Bristol-Myers Squibb Canada and Pfizer Canada Inc. Alliance
    Indication(s) Thromboembolic events (venous), treatment and prevention of recurrence
    Submission type Initial
    Project Number SR0397-000
    Date submission received 2014-09-18 (Tentative)
    Call for patient input 2014-08-20
    Patient input deadline 2014-10-09
    Status Active
    Recommendation

    Submission status report

  39. Apixaban

    Brand name Eliquis
    Manufacturer Bristol-Myers Squibb Canada and Pfizer Canada Inc. Alliance
    Indication(s) Thromboembolic events prevention, (atrial fibrillation)
    Submission type New Indication
    Project Number SR0288
    Date submission received 2012-09-25
    Call for patient input 2012-09-07
    Patient input deadline 2012-10-15
    Status Complete
    Date recommendation issued 2013-03-20
    Recommendation List with criteria/condition

    Submission status report

    Recommendation and reasons

  40. Apixaban

    Brand name Eliquis
    Manufacturer Bristol-Myers Squibb and Pfizer Canada Alliance
    Indication(s) Thromboembolic events, (venous) prevention
    Submission type Initial
    Project Number S0264
    Date submission received 2011-12-20
    Call for patient input 2011-12-19
    Patient input deadline 2012-01-17
    Status Complete
    Date recommendation issued 2012-06-14
    Recommendation List with criteria/condition

    Submission status report

    Recommendation and reasons

  41. Apremilast

    Brand name Otezla
    Manufacturer Celgene
    Indication(s) Psoriasis, moderate to severe plaque
    Submission type Initial
    Project Number SR0400-000
    Date submission received 2014-10-08
    Call for patient input 2014-09-04
    Patient input deadline 2014-10-24
    Status Active
    Recommendation

    Submission status report

  42. Aprepitant

    Brand name Emend
    Manufacturer Merck Frosst Canada Ltd.
    Indication(s) Nausea and Vomiting, Chemotherapy induced
    Submission type Initial
    Project Number S0109
    Date submission received 2007-08-29
    Status Complete
    Date recommendation issued 2008-02-20
    Recommendation List with criteria/condition
    Plain language recommendation Plain language recommendation
    Summary of CEDAC Discussion Summary of CEDAC Discussion
    Overview of CDR reports Overview of CDR reports

    Submission status report

    Recommendation and reasons

  43. Aripiprazole

    Brand name Abilify Maintena
    Manufacturer Otsuka Canada Pharmaceutical Inc. & Lundbeck Canada Inc.
    Indication(s) Schizophrenia
    Submission type Initial
    Project Number SR0366-000
    Date submission received 2014-01-06
    Call for patient input 2014-07-09
    Patient input deadline 2014-08-28
    Status Active
    Recommendation

    Submission status report

  44. Aripiprazole

    Brand name Abilify
    Manufacturer Bristol-Myers Squibb Canada
    Indication(s) Depression, Major Depressive Disorder (MDD)
    Submission type Initial
    Project Number SR0354
    Date submission received 2013-10-01
    Call for patient input 2013-10-01
    Patient input deadline 2013-10-23
    Status Active
    Date recommendation issued 2014-10-22
    Recommendation Do not list

    Submission status report

    Recommendation and reasons

  45. Aripiprazole

    Brand name Abilify
    Manufacturer Bristol-Myers Squibb
    Indication(s) Schizophrenia and Related Psychotic Disorders
    Submission type Request for Advice
    Project Number S0226
    Date submission received 2011-03-29
    Status Complete
    Date recommendation issued 2011-07-18
    Recommendation List with criteria/condition
    Plain language recommendation Plain language recommendation

    Submission status report

    Recommendation and reasons

  46. Aripiprazole

    Brand name Abilify
    Manufacturer Bristol-Myers Squibb Canada
    Indication(s) Schizophrenia
    Submission type Initial
    Project Number S0183
    Date submission received 2009-11-06
    Status Complete
    Date recommendation issued 2010-04-27
    Recommendation Do not list

    Submission status report

    Recommendation and reasons

  47. Asenapine

    Brand name Saphris
    Manufacturer Lundbeck Canada Inc.
    Indication(s) Schizophrenia
    Submission type Initial
    Project Number S0262-000
    Date submission received 2011-12-12
    Call for patient input 2011-12-02
    Patient input deadline 2012-01-09
    Status Complete
    Date recommendation issued 2012-06-14
    Recommendation Do not list

    Submission status report

    Recommendation and reasons

  48. Asenapine

    Brand name Saphris
    Manufacturer Lundbeck Canada Inc.
    Indication(s) Bipolar I disorder
    Submission type Initial
    Project Number S0262-001
    Date submission received 2011-12-12
    Call for patient input 2011-12-02
    Patient input deadline 2012-01-09
    Status Complete
    Date recommendation issued 2012-06-14
    Recommendation List with criteria/condition

    Submission status report

    Recommendation and reasons

  49. Atazanavir

    Brand name Reyataz
    Manufacturer Bristol Myers Squibb
    Indication(s) HIV infection
    Submission type Initial
    Project Number S0002
    Date submission received 2003-12-16
    Status Complete
    Date recommendation issued 2004-05-27
    Recommendation List in a similar manner to other drugs in class

    Submission status report

    Recommendation and reasons

  50. Atomoxetine hydrochloride

    Brand name Strattera
    Manufacturer Eli Lilly Canada Inc.
    Indication(s) Attention deficit hyperactivity disorder
    Submission type Request for Advice
    Project Number S0085
    Date submission received 2006-09-25
    Status Complete
    Recommendation

    Submission status report

  51. Atomoxetine hydrochloride

    Brand name Strattera
    Manufacturer Eli Lilly Canada Inc.
    Indication(s) Attention deficit hyperactivity disorder
    Submission type Initial
    Project Number S0031
    Date submission received 2005-01-25
    Status Complete
    Date recommendation issued 2005-09-28
    Recommendation Do not list

    Submission status report

    Recommendation and reasons

  52. Azelaic acid

    Brand name Finacea
    Manufacturer Bayer Inc.
    Indication(s) Rosacea
    Submission type Initial
    Project Number S0209
    Date submission received 2010-08-31
    Call for patient input 2010-08-31
    Patient input deadline 2010-09-22
    Status Complete
    Date recommendation issued 2011-02-16
    Recommendation List
    Plain language recommendation Plain language recommendation

    Submission status report

    Recommendation and reasons

  53. Azelastine HCl and fluticasone propionate

    Brand name Dymista
    Manufacturer Meda Pharmaceuticals Ltd.
    Indication(s) Seasonal allergic rhinitis and rhino-conjunctivitis
    Submission type Initial
    Project Number TBC
    Date submission received 2014-12-09
    Call for patient input 2014-11-07
    Patient input deadline 2015-01-05
    Status Received
    Recommendation

    Submit Patient Input


    Submission status report

  54. Azilsartan medoxomil

    Brand name Edarbi
    Manufacturer Takeda Canada Inc.
    Indication(s) Hypertension, essential
    Submission type Initial
    Project Number SR0317
    Date submission received 2013-03-08
    Call for patient input 2013-03-08
    Patient input deadline 2013-03-29
    Status Complete
    Date recommendation issued 2013-10-17
    Recommendation Do not list at the submitted price

    Submission status report

    Recommendation and reasons

  55. Azilsartan medoxomil + chlorthalidone

    Brand name Edarbyclor
    Manufacturer Takeda Canada Inc.
    Indication(s) Hypertension, essential
    Submission type Initial
    Project Number SR0318
    Date submission received 2013-03-08
    Call for patient input 2013-03-08
    Patient input deadline 2013-03-29
    Status Complete
    Date recommendation issued 2013-10-17
    Recommendation Do not list

    Submission status report

    Recommendation and reasons

  56. Aztreonam for inhalation solution

    Brand name Cayston
    Manufacturer Gilead Sciences Canada Inc.
    Indication(s) Cystic fibrosis (CF) with chronic pulmonary pseudomonas aeruginosa infections
    Submission type Initial
    Project Number S0220
    Date submission received 2010-12-02
    Call for patient input 2010-11-26
    Patient input deadline 2011-01-31
    Status Complete
    Date recommendation issued 2011-07-18
    Recommendation List with criteria/condition
    Plain language recommendation Plain language recommendation

    Submission status report

    Recommendation and reasons

  57. Belimumab

    Brand name Benlysta
    Manufacturer GlaxoSmithKline Inc.
    Indication(s) Systemic lupus erythematosus
    Submission type Initial
    Project Number S0251
    Date submission received 2011-09-19
    Call for patient input 2011-08-30
    Patient input deadline 2011-10-11
    Status Complete
    Date recommendation issued 2012-04-25
    Recommendation Do not list

    Submission status report

    Recommendation and reasons

  58. Boceprevir

    Brand name Victrelis
    Manufacturer Merck Canada Inc.
    Indication(s) Hepatitis C infection, chronic
    Submission type Request for Advice
    Project Number SF0312
    Date submission received 2013-02-19
    Status Complete
    Date recommendation issued 2013-06-13
    Recommendation List with clinical criteria and/or conditions

    Submission status report

    Recommendation and reasons

  59. Boceprevir

    Brand name Victrelis
    Manufacturer Merck Canada Inc.
    Indication(s) Hepatitis C, chronic
    Submission type Request for Advice
    Project Number SF0303
    Date submission received 2012-12-21
    Status Complete
    Date recommendation issued 2013-06-13
    Recommendation List with clinical criteria and/or conditions

    Submission status report

    Recommendation and reasons

  60. Boceprevir

    Brand name Victrelis
    Manufacturer Merck Canada Inc.
    Indication(s) Hepatitis C, chronic
    Submission type Pre-NOC
    Project Number S0231
    Date submission received 2011-05-03
    Call for patient input 2011-04-25
    Patient input deadline 2011-05-26
    Status Complete
    Date recommendation issued 2011-10-24
    Recommendation List with criteria/condition
    Plain language recommendation Plain language recommendation

    Submission status report

    Recommendation and reasons

  61. Brimonidine tartrate / timolol maleate

    Brand name Combigan Ophthalmic Solution
    Manufacturer Allergan Canada Inc.
    Indication(s) Glaucoma
    Submission type Initial
    Project Number S0001
    Date submission received 2003-12-15
    Status Complete
    Date recommendation issued 2004-05-27
    Recommendation List with criteria/condition

    Submission status report

    Recommendation and reasons

  62. Brinzolamide / brimonidine

    Brand name Simbrinza
    Manufacturer Alcon Canada Inc.
    Indication(s) Glaucoma and ocular hypertension
    Submission type Pre-NOC
    Project Number SR0403
    Date submission received 2014-11-03
    Call for patient input 2014-10-01
    Patient input deadline 2014-11-20
    Status Active
    Recommendation

    Submission status report

  63. Brinzolamide and timolol maleate suspension

    Brand name Azarga
    Manufacturer Alcon Canada Inc.
    Indication(s) Glaucoma and ocular hypertension
    Submission type Initial
    Project Number S0173
    Date submission received 2009-08-28
    Status Complete
    Date recommendation issued 2010-02-18
    Recommendation List in a similar manner to other drugs in class

    Submission status report

    Recommendation and reasons

  64. Buprenorphine transdermal patch

    Brand name BuTrans
    Manufacturer Purdue Pharma
    Indication(s) Pain, persistent (moderate intensity)
    Submission type Resubmission #1
    Project Number S0233
    Date submission received 2011-05-09
    Status Complete
    Date recommendation issued 2011-09-28
    Recommendation Do not list
    Plain language recommendation Plain language recommendation

    Submission status report

    Recommendation and reasons

  65. Buprenorphine transdermal patch

    Brand name BuTrans
    Manufacturer Purdue Pharma
    Indication(s) Pain, persistent (moderate intensity)
    Submission type Initial
    Project Number S0211
    Date submission received 2010-10-15
    Call for patient input 2010-10-19
    Patient input deadline 2010-11-05
    Status Stopped
    Recommendation

    Submission status report

  66. Buprenorphine / naloxone

    Brand name Suboxone
    Manufacturer Schering-Plough Canada Inc
    Indication(s) Opioid drug dependence (Substitution treatment)
    Submission type Initial
    Project Number S0128
    Date submission received 2008-03-06
    Status Complete
    Date recommendation issued 2008-09-24
    Recommendation List with criteria/condition

    Submission status report

    Recommendation and reasons

  67. Butoconazole nitrate

    Brand name Gynazole.1
    Manufacturer Ferring Pharmaceuticals
    Indication(s) Vaginal infection
    Submission type Initial
    Project Number S0017
    Date submission received 2004-06-30
    Status Complete
    Date recommendation issued 2005-01-26
    Recommendation Do not list

    Submission status report

    Recommendation and reasons

  68. Calcitriol

    Brand name Silkis
    Manufacturer Galderma Canada Inc.
    Indication(s) Psoriasis, mild to moderate plaque
    Submission type Initial
    Project Number S0199
    Date submission received 2010-03-15
    Status Complete
    Date recommendation issued 2010-09-22
    Recommendation Do not list

    Submission status report

    Recommendation and reasons

  69. Canagliflozin

    Brand name Invokana
    Manufacturer Janssen Inc.
    Indication(s) Diabetes Mellitus, Type 2
    Submission type Pre-NOC
    Project Number SR0370-000
    Date submission received 2014-02-24
    Call for patient input 2014-07-09
    Patient input deadline 2014-08-28
    Status Active
    Recommendation

    Submission status report

  70. Canagliflozin

    Brand name Invokana
    Manufacturer Janssen Inc.
    Indication(s) Diabetes mellitus, type 2
    Submission type Initial
    Project Number SR0335
    Date submission received 2013-06-05
    Status Withdrawn
    Recommendation

    Submission status report

  71. Canakinumab

    Brand name Ilaris
    Manufacturer Novartis Pharmaceuticals Canada Inc.
    Indication(s) Cryopyrin-Associated Periodic Syndrome (CAPS)
    Submission type Initial
    Project Number S0204
    Date submission received 2010-07-07
    Call for patient input 2010-06-30
    Patient input deadline 2010-07-28
    Status Complete
    Date recommendation issued 2011-01-26
    Recommendation Do not list
    Plain language recommendation Plain language recommendation

    Submission status report

    Recommendation and reasons

  72. Carbidopa, levodopa and entacapone

    Brand name Stalevo
    Manufacturer Novartis Pharmaceuticals Canada Inc.
    Indication(s) Parkinsons Disease
    Submission type Initial
    Project Number S0131
    Date submission received 2008-04-15
    Status Complete
    Date recommendation issued 2008-10-16
    Recommendation List in a similar manner

    Submission status report

    Recommendation and reasons

  73. Certolizumab pegol

    Brand name Cimzia
    Manufacturer UCB Canada Inc.
    Indication(s) Arthritis, psoriatic
    Submission type New Indication
    Project Number SR0394
    Date submission received 2014-09-02
    Call for patient input 2014-07-31
    Patient input deadline 2014-09-22
    Status Active
    Recommendation

    Submission status report

  74. Certolizumab pegol

    Brand name Cimzia
    Manufacturer UCB Canada Inc.
    Indication(s) Ankylosing spondylitis
    Submission type Initial
    Project Number SR0385-000
    Date submission received 2014-06-23
    Call for patient input 2014-07-09
    Patient input deadline 2014-08-28
    Status Active
    Recommendation

    Submission status report

  75. Certolizumab pegol

    Brand name Cimzia
    Manufacturer UCB Pharma Canada Inc.
    Indication(s) Arthritis, rheumatoid
    Submission type Initial
    Project Number S0175
    Date submission received 2009-09-03
    Status Complete
    Date recommendation issued 2010-05-27
    Recommendation Do not list

    Submission status report

    Recommendation and reasons

  76. Ciclesonide

    Brand name Alvesco
    Manufacturer Altana Pharma Inc.
    Indication(s) asthma
    Submission type Initial
    Project Number S0074
    Date submission received 2006-07-24
    Status Complete
    Date recommendation issued 2006-12-20
    Recommendation List

    Submission status report

    Recommendation and reasons

  77. Ciclesonide nasal spray

    Brand name Omnaris
    Manufacturer Nycomed Canada Inc.
    Indication(s) Allergic Rhinitis (seasonal and perennial)
    Submission type Initial
    Project Number S0137
    Date submission received 2008-05-07
    Status Complete
    Date recommendation issued 2008-11-12
    Recommendation Do not list

    Submission status report

    Recommendation and reasons

  78. Cinacalcet hydrochloride

    Brand name Sensipar
    Manufacturer Amgen Canada Inc.
    Indication(s) Secondary hyper-parathyroidism in chronic kidney disease
    Submission type Initial
    Project Number S0018
    Date submission received 2004-08-20
    Status Complete
    Date recommendation issued 2005-03-23
    Recommendation Do not list

    Submission status report

    Recommendation and reasons

  79. Ciprofloxacin hydrochloride & dexamethasone otic suspension

    Brand name Ciprodex
    Manufacturer Alcon Canada Inc.
    Indication(s) Otitis media with otorrhea & otitis externa, acute
    Submission type Request for Advice
    Project Number S0101
    Date submission received 2007-06-15
    Status Complete
    Date recommendation issued 2007-10-18
    Recommendation List with criteria/condition

    Submission status report

    Recommendation and reasons

  80. Ciprofloxacin hydrochloride and dexamethasone otic suspension

    Brand name Ciprodex
    Manufacturer Alcon Canada Inc.
    Indication(s) Otitis media with otorrhea & otitis externa, acute
    Submission type Initial
    Project Number S0014
    Date submission received 2004-06-11
    Status Complete
    Date recommendation issued 2005-01-26
    Recommendation Do not list

    Submission status report

    Recommendation and reasons

  81. Clostridium botulinum neurotoxin type A, free from complexing proteins

    Brand name Xeomin
    Manufacturer Merz Pharmaceuticals GmbH
    Indication(s) Blepharospasm
    Submission type Initial
    Project Number S0168
    Date submission received 2009-06-12
    Status Complete
    Date recommendation issued 2009-12-16
    Recommendation List in a similar manner

    Submission status report

    Recommendation and reasons

  82. Clostridium botulinum neurotoxin type A, free from complexing proteins

    Brand name Xeomin
    Manufacturer Merz Pharmaceuticals GmbH
    Indication(s) Cervical Dystonia
    Submission type Initial
    Project Number S0192
    Date submission received 2009-06-12
    Status Complete
    Date recommendation issued 2009-12-16
    Recommendation List in a similar manner

    Submission status report

    Recommendation and reasons

  83. Clostridium botulinum neurotoxin type A, free from complexing proteins

    Brand name Xeomin
    Manufacturer Merz Pharmaceuticals GmbH
    Indication(s) Spasticity, Post-stroke
    Submission type Initial
    Project Number S0193
    Date submission received 2009-06-12
    Status Complete
    Date recommendation issued 2009-12-16
    Recommendation Do not list

    Submission status report

    Recommendation and reasons

  84. Colesevelam hydrochloride

    Brand name Lodalis
    Manufacturer Valeant Canada LP
    Indication(s) Hypercholesterolemia
    Submission type Initial
    Project Number SR0274
    Date submission received 2012-04-27
    Call for patient input 2012-04-16
    Patient input deadline 2012-05-22
    Status Complete
    Date recommendation issued 2012-12-19
    Recommendation Do not list at the submitted price

    Submission status report

    Recommendation and reasons

  85. Collagenase clostridium histolyticum

    Brand name Xiaflex
    Manufacturer Auxilium Pharmaceuticals, Inc. & Actelion Pharmaceuticals Canada Inc.
    Indication(s) Dupuytren’s contracture with a palpable cord
    Submission type Initial
    Project Number SR0287
    Date submission received 2012-08-30
    Call for patient input 2012-08-20
    Patient input deadline 2012-09-24
    Status Complete
    Date recommendation issued 2013-03-27
    Recommendation List with clinical criteria and/or conditions

    Submission status report

    Recommendation and reasons

  86. Cyclosporine

    Brand name Restasis ophthalmic emulsion
    Manufacturer Allergan Inc.
    Indication(s) Dry eye disease, Moderate to moderately severe
    Submission type Initial
    Project Number S0222
    Date submission received 2010-12-17
    Call for patient input 2010-12-02
    Patient input deadline 2011-02-07
    Status Complete
    Date recommendation issued 2011-07-18
    Recommendation Do not list
    Plain language recommendation Plain language recommendation

    Submission status report

    Recommendation and reasons

  87. Dabigatran etexilate

    Brand name Pradaxa
    Manufacturer Boehringer Ingelheim (Canada) Ltd
    Indication(s) Atrial fibrillation prevention of stroke and systemic embolism
    Submission type Request for Advice
    Project Number SF0320-000
    Date submission received 2013-03-18
    Status Complete
    Date recommendation issued 2013-07-18
    Recommendation List with criteria/condition

    Submission status report

    Recommendation and reasons

  88. Dabigatran etexilate

    Brand name Pradaxa
    Manufacturer Boehringer Ingelheim
    Indication(s) Atrial fibrillation prevention of stroke and systemic embolism
    Submission type New Indication
    Project Number S0214
    Date submission received 2010-10-28
    Call for patient input 2010-10-29
    Patient input deadline 2010-11-18
    Status Complete
    Date recommendation issued 2011-06-22
    Recommendation List with criteria/condition
    Plain language recommendation Plain language recommendation

    Submission status report

    Recommendation and reasons

  89. Dabigatran etexilate

    Brand name Pradaxa
    Manufacturer Boehringer-Ingelheim (Canada) Ltd.
    Indication(s) Atrial fibrillation prevention of stroke and systemic embolism
    Submission type Pre-NOC - New Indication
    Project Number S0202
    Date submission received 2010-05-31
    Call for patient input 2010-06-04
    Patient input deadline 2010-06-25
    Status Rejected
    Recommendation

    Submission status report

  90. Dabigatran etexilate

    Brand name Pradaxa
    Manufacturer Boehringer Ingelheim (Canada) Ltd.
    Indication(s) Thromboembolism (venous), prevention
    Submission type Initial
    Project Number S0140
    Date submission received 2008-07-08
    Status Complete
    Date recommendation issued 2009-01-28
    Recommendation Do not list

    Submission status report

    Recommendation and reasons

  91. Daptomycin

    Brand name Cubicin
    Manufacturer Cubist Pharmaceuticals Inc.
    Indication(s) Skin and skin structure infections & bacteremia
    Submission type Initial
    Project Number S0127
    Date submission received 2008-03-06
    Status Complete
    Date recommendation issued 2008-09-24
    Recommendation Do not list

    Submission status report

    Recommendation and reasons

  92. Darifenacin hydrobromide

    Brand name Enablex
    Manufacturer Novartis Pharmaceuticals Canada Inc.
    Indication(s) Bladder, overactive
    Submission type Resubmission #1
    Project Number S0147
    Date submission received 2008-10-01
    Status Complete
    Date recommendation issued 2009-04-16
    Recommendation List with criteria/condition

    Submission status report

    Recommendation and reasons

  93. Darifenacin hydrobromide

    Brand name Enablex
    Manufacturer Novartis Pharmaceuticals Canada Inc.
    Indication(s) Bladder, overactive
    Submission type Initial
    Project Number S0061
    Date submission received 2006-04-26
    Status Complete
    Date recommendation issued 2006-10-19
    Recommendation Do not list

    Submission status report

    Recommendation and reasons

  94. Darunavir

    Brand name Prezista
    Manufacturer Janssen-Ortho Inc.
    Indication(s) HIV infection (Pediatric)
    Submission type New Indication
    Project Number S0194
    Date submission received 2009-12-22
    Status Complete
    Date recommendation issued 2010-06-17
    Recommendation List with criteria/condition

    Submission status report

    Recommendation and reasons

  95. Darunavir

    Brand name Prezista
    Manufacturer Janssen-Ortho Inc.
    Indication(s) HIV (treatment naive)
    Submission type New Indication
    Project Number S0163
    Date submission received 2009-03-27
    Status Complete
    Date recommendation issued 2009-10-14
    Recommendation List with criteria/condition

    Submission status report

    Recommendation and reasons

  96. Darunavir

    Brand name Prezista
    Manufacturer Janssen-Ortho Inc.
    Indication(s) HIV infection
    Submission type Initial
    Project Number S0072
    Date submission received 2006-08-29
    Status Complete
    Date recommendation issued 2007-02-14
    Recommendation List with criteria/condition

    Submission status report

    Recommendation and reasons

  97. Darunavir / cobicistat

    Brand name TBC
    Manufacturer Janssen Inc.
    Indication(s) HIV infection
    Submission type Pre-NOC
    Project Number SR0378-000
    Date submission received 2014-04-04
    Status Withdrawn
    Recommendation

    Submission status report

  98. Darunavir / cobicistat

    Brand name Prezcobix
    Manufacturer Janssen Inc.
    Indication(s) HIV Infection
    Submission type Pre-NOC
    Project Number SR0381-000
    Date submission received 2014-05-22
    Call for patient input 2014-07-09
    Patient input deadline 2014-08-28
    Status Active
    Recommendation

    Submission status report

  99. Deferasirox

    Brand name Exjade
    Manufacturer Novartis Pharmaceuticals Canada Inc.
    Indication(s) Iron overload
    Submission type Initial
    Project Number S0081
    Date submission received 2006-10-26
    Status Complete
    Date recommendation issued 2007-04-19
    Recommendation List with criteria/condition

    Submission status report

    Recommendation and reasons

  100. Delta-9-tetrahydrocannabinol / cannabidiol

    Brand name Sativex
    Manufacturer GW Pharma Ltd.
    Indication(s) Pain, cancer (adjunctive analgesia to maximum tolerated strong opioids)
    Submission type Resubmission #1
    Project Number S0106
    Date submission received 2007-08-07
    Status Complete
    Date recommendation issued 2008-02-20
    Recommendation Do not list

    Submission status report

    Recommendation and reasons

  101. Delta-9-tetrahydrocannabinol / cannabidiol

    Brand name Sativex
    Manufacturer GW Pharma Ltd.
    Indication(s) Pain, Neuropathic (adjunctive) in MS.
    Submission type Initial
    Project Number S0092
    Date submission received 2007-02-27
    Status Complete
    Date recommendation issued 2007-09-26
    Recommendation Do not list

    Submission status report

    Recommendation and reasons

  102. Denosumab

    Brand name XGEVA
    Manufacturer Amgen Canada Inc.
    Indication(s) Prevention of skeletal-related events due to bone metastases from solid tumours
    Submission type New Indication
    Project Number S0235
    Date submission received 2011-06-06
    Call for patient input 2011-05-27
    Patient input deadline 2011-06-24
    Status Complete
    Date recommendation issued 2011-11-16
    Recommendation List with criteria/condition
    Plain language recommendation Plain language recommendation

    Submission status report

    Recommendation and reasons

  103. Denosumab

    Brand name Prolia
    Manufacturer Amgen Canada Inc.
    Indication(s) Osteoporosis, postmenopausal women
    Submission type Initial
    Project Number S0208
    Date submission received 2010-08-26
    Call for patient input 2010-08-13
    Patient input deadline 2010-09-17
    Status Complete
    Date recommendation issued 2011-03-30
    Recommendation List with criteria/condition
    Plain language recommendation Plain language recommendation

    Submission status report

    Recommendation and reasons

  104. Desvenlafaxine succinate

    Brand name Pristiq
    Manufacturer Wyeth Canada
    Indication(s) Depressive, Major Disorder (MDD)
    Submission type Initial
    Project Number S0159
    Date submission received 2009-03-05
    Status Complete
    Date recommendation issued 2009-09-23
    Recommendation Do not list

    Submission status report

    Recommendation and reasons

  105. Dexamethasone intravitreal implant

    Brand name Ozurdex
    Manufacturer Allergan
    Indication(s) Macular edema following central retinal vein occlusion
    Submission type Initial
    Project Number S0247
    Date submission received 2011-09-01
    Call for patient input 2011-08-19
    Patient input deadline 2011-09-23
    Status Complete
    Date recommendation issued 2012-04-25
    Recommendation Do not list

    Submission status report

    Recommendation and reasons

  106. Dienogest

    Brand name Visanne
    Manufacturer Bayer Inc.
    Indication(s) Pain (pelvic) associated with endometriosis
    Submission type Initial
    Project Number S0255
    Date submission received 2011-10-18
    Call for patient input 2011-10-18
    Patient input deadline 2011-11-08
    Status Complete
    Date recommendation issued 2012-04-19
    Recommendation List with criteria/condition

    Submission status report

    Recommendation and reasons

  107. Dimethyl fumarate

    Brand name Tecfidera
    Manufacturer Biogen Idec Canada Inc.
    Indication(s) Multiple Sclerosis, relapsing
    Submission type Pre-NOC
    Project Number SR0309
    Date submission received 2013-02-04
    Call for patient input 2013-01-18
    Patient input deadline 2013-03-04
    Status Complete
    Date recommendation issued 2013-09-25
    Recommendation List with clinical criteria and/or conditions

    Submission status report

    Recommendation and reasons

  108. Dolutegravir

    Brand name Tivicay
    Manufacturer ViiV Healthcare ULC
    Indication(s) HIV infection
    Submission type Pre-NOC
    Project Number SR0357
    Date submission received 2013-10-18
    Call for patient input 2013-09-26
    Patient input deadline 2013-11-08
    Status Active
    Date recommendation issued 2014-08-20
    Recommendation List

    Submission status report

    Recommendation and reasons

  109. Dolutegravir / abacavir / lamivudine

    Brand name Triumeq
    Manufacturer ViiV Healthcare
    Indication(s) HIV Infection
    Submission type Pre-NOC
    Project Number SR0387
    Date submission received 2014-07-31
    Call for patient input 2014-07-09
    Patient input deadline 2014-08-28
    Status Active
    Recommendation

    Submission status report

  110. Doxycycline monohydrate

    Brand name Apprilon
    Manufacturer Galderma Canada Inc.
    Indication(s) Rosacea treatment
    Submission type Initial
    Project Number SR0279
    Date submission received 2012-04-27
    Call for patient input 2012-04-19
    Patient input deadline 2012-05-22
    Status Complete
    Date recommendation issued 2013-03-27
    Recommendation Do not list

    Submission status report

    Recommendation and reasons

  111. Dronedarone hydrochloride

    Brand name Multaq
    Manufacturer Sanofi-Aventis Canada Inc.
    Indication(s) Atrial fibrillation
    Submission type Initial
    Project Number S0177
    Date submission received 2009-09-18
    Status Complete
    Date recommendation issued 2010-05-27
    Recommendation Do not list

    Submission status report

    Recommendation and reasons

  112. Drospirenone / ethinyl estradiol

    Brand name Yasmin
    Manufacturer Berlex Canada Inc.
    Indication(s) Contraceptive, oral
    Submission type Initial
    Project Number S0029
    Date submission received 2005-01-20
    Status Complete
    Date recommendation issued 2005-06-16
    Recommendation List

    Submission status report

    Recommendation and reasons

  113. Duloxetine hydrochloride

    Brand name Cymbalta
    Manufacturer Eli Lilly Canada Inc.
    Indication(s) Pain, Neuropathic, Diabetic
    Submission type Initial
    Project Number S0126
    Date submission received 2008-02-08
    Status Complete
    Date recommendation issued 2008-08-14
    Recommendation List with criteria/condition

    Submission status report

    Recommendation and reasons

  114. Duloxetine hydrochloride

    Brand name Cymbalta
    Manufacturer Eli Lilly Canada Inc.
    Indication(s) Depressive, Major Disorder (MDD)
    Submission type Initial
    Project Number S0125
    Date submission received 2008-02-08
    Status Complete
    Date recommendation issued 2008-08-14
    Recommendation Do not list

    Submission status report

    Recommendation and reasons

  115. Dutasteride

    Brand name Avodart
    Manufacturer GlaxoSmithKline Inc.
    Indication(s) Prostatic hyperplasia, benign
    Submission type Initial
    Project Number S0019
    Date submission received 2004-08-24
    Status Complete
    Date recommendation issued 2005-01-20
    Recommendation List in a similar manner to other drugs in class

    Submission status report

    Recommendation and reasons

  116. Eculizumab

    Brand name Soliris
    Manufacturer Alexion Pharma Canada
    Indication(s) Hemolytic Uremic Syndrome, Atypical
    Submission type Pre-NOC
    Project Number SR0304
    Date submission received 2013-01-07
    Call for patient input 2012-12-06
    Patient input deadline 2013-01-28
    Status Complete
    Date recommendation issued 2013-07-18
    Recommendation Do not list

    Submission status report

    Recommendation and reasons

  117. Eculizumab

    Brand name Soliris
    Manufacturer Alexion Pharmaceuticals Inc.
    Indication(s) Paroxysmal nocturnal hemoglobinuria (PNH)
    Submission type Initial
    Project Number S0176
    Date submission received 2009-09-18
    Status Complete
    Date recommendation issued 2010-02-18
    Recommendation Do not list

    Submission status report

    Recommendation and reasons

  118. Efalizumab

    Brand name Raptiva
    Manufacturer Serono Canada Inc.
    Indication(s) Psoriasis, moderate to severe chronic plaque
    Submission type Request for Advice
    Project Number S0102
    Date submission received 2007-06-19
    Status Complete
    Recommendation

    Submission status report

  119. Efalizumab

    Brand name Raptiva
    Manufacturer Serono Canada Inc.
    Indication(s) Psoriasis, moderate to severe chronic plaque
    Submission type Initial
    Project Number S0043
    Date submission received 2005-10-25
    Status Complete
    Date recommendation issued 2006-08-24
    Recommendation List with criteria/condition

    Submission status report

    Recommendation and reasons

  120. Efavirenz, emtricitabine, tenofovir disoproxil fumarate

    Brand name Atripla
    Manufacturer Bristol-Myers Squibb and Gilead Sciences
    Indication(s) HIV
    Submission type Initial
    Project Number S0111
    Date submission received 2007-10-30
    Status Complete
    Date recommendation issued 2008-04-17
    Recommendation List with criteria/condition

    Submission status report

    Recommendation and reasons

  121. Eletriptan hydrobromide

    Brand name Relpax
    Manufacturer Pfizer Canada Inc.
    Indication(s) Migraine
    Submission type Initial
    Project Number S0021
    Date submission received 2004-09-21
    Status Complete
    Date recommendation issued 2005-03-23
    Recommendation Do not list

    Submission status report

    Recommendation and reasons

  122. Elosulfase alfa

    Brand name Vimizim
    Manufacturer BioMarin Pharmaceutical (Canada) Inc.
    Indication(s) Mucopolysaccharidosis IVA (Morquio A syndrome)
    Submission type Initial
    Project Number SR0389
    Date submission received 2014-08-05
    Call for patient input 2014-07-09
    Patient input deadline 2014-08-28
    Status Active
    Recommendation

    Submission status report

  123. Eltrombopag

    Brand name Revolade
    Manufacturer GlaxoSmithKline
    Indication(s) Thrombocytopenia associated with chronic hepatitis c infection
    Submission type New Indication
    Project Number SR0377-000
    Date submission received 2014-03-31
    Call for patient input 2014-07-09
    Patient input deadline 2014-08-28
    Status Active
    Recommendation

    Submission status report

  124. Eltrombopag olamine

    Brand name Revolade
    Manufacturer GlaxoSmithKline
    Indication(s) Thrombocytopenic purpura chronic immune (idiopathic)
    Submission type Initial
    Project Number S0230
    Date submission received 2011-04-26
    Call for patient input 2011-04-26
    Patient input deadline 2011-05-17
    Status Complete
    Date recommendation issued 2011-10-24
    Recommendation Do not list
    Plain language recommendation Plain language recommendation

    Submission status report

    Recommendation and reasons

  125. Elvitegravir / Cobicistat / Emtricitabine / Tenofovir Disoproxil Fumarate

    Brand name Stribild
    Manufacturer Gilead Sciences Canada Inc.
    Indication(s) HIV-1 infection
    Submission type Initial
    Project Number SR0301
    Date submission received 2012-11-30
    Call for patient input 2012-11-19
    Patient input deadline 2012-12-21
    Status Complete
    Date recommendation issued 2013-05-15
    Recommendation List with clinical criteria and/or conditions

    Submission status report

    Recommendation and reasons

  126. Emtricitabine / rilpivirine / tenofovir disoproxil fumarate

    Brand name COMPLERA
    Manufacturer Gilead Science Canada Ltd.
    Indication(s) HIV-1 infection in antiretroviral treatment- naïve adults
    Submission type Initial
    Project Number S0256
    Date submission received 2011-10-19
    Call for patient input 2011-10-11
    Patient input deadline 2011-11-09
    Status Complete
    Date recommendation issued 2012-04-19
    Recommendation List

    Submission status report

    Recommendation and reasons

  127. Emtricitabine / tenofovir disoproxil fumarate

    Brand name Truvada
    Manufacturer Gilead Sciences Canada Inc.
    Indication(s) HIV infection
    Submission type Request for Advice
    Project Number S0138
    Date submission received 2008-07-07
    Status Complete
    Date recommendation issued 2008-12-17
    Recommendation List with criteria/condition

    Submission status report

    Recommendation and reasons

  128. Emtricitabine / tenofovir disoproxil fumarate

    Updated recommendation issued 2008-12-17
    Brand name Truvada
    Manufacturer Gilead Sciences Canada Inc.
    Indication(s) HIV infection
    Submission type Initial
    Project Number S0063
    Date submission received 2006-05-29
    Status Complete
    Date recommendation issued 2006-10-25
    Recommendation List with criteria/condition

    Submission status report

    Recommendation and reasons

    Recommendation and reasons

  129. Entecavir

    Brand name Baraclude
    Manufacturer Bristol-Myers Squibb Canada
    Indication(s) Hepatitis B (chronic)
    Submission type Initial
    Project Number S0089
    Date submission received 2006-12-12
    Status Complete
    Date recommendation issued 2007-11-28
    Recommendation List with criteria/condition

    Submission status report

    Recommendation and reasons

  130. Eplerenone

    Brand name Inspra
    Manufacturer Pfizer Canada Inc.
    Indication(s) Heart failure, NYHA class II
    Submission type New Indication
    Project Number SR0342
    Date submission received 2013-07-12
    Call for patient input 2013-07-12
    Patient input deadline 2013-08-02
    Status Complete
    Date recommendation issued 2014-04-24
    Recommendation Do not list at the submitted price

    Submission status report

    Clinical Report

    Pharmacoeconomic Report

    Recommendation and reasons

  131. Eplerenone

    Brand name Inspra
    Manufacturer Pfizer Canada Inc.
    Indication(s) Post myocardial infarction
    Submission type Initial
    Project Number S0165
    Date submission received 2009-05-06
    Status Complete
    Date recommendation issued 2009-11-25
    Recommendation Do not list

    Submission status report

    Recommendation and reasons

  132. Eprosartan mesylate / hydrochlorothiazide

    Brand name Teveten Plus
    Manufacturer Solvay Pharma Inc.
    Indication(s) Hypertension, Essential
    Submission type Initial
    Project Number S0016
    Date submission received 2004-07-08
    Status Complete
    Date recommendation issued 2004-12-15
    Recommendation List in a similar manner to other drugs in class

    Submission status report

    Recommendation and reasons

  133. Erlotinib

    Brand name Tarceva
    Manufacturer Hoffmann-La Roche Limited
    Indication(s) Cancer, Lung , non-small cell
    Submission type Initial
    Project Number S0037
    Date submission received 2005-07-19
    Status Complete
    Date recommendation issued 2005-12-07
    Recommendation List with criteria/condition

    Submission status report

    Recommendation and reasons

  134. Escitalopram oxalate

    Brand name Cipralex
    Manufacturer Lundbeck Canada Inc.
    Indication(s) Depression, Major Depressive Disorder (MDD)
    Submission type Resubmission #1
    Project Number S0064
    Date submission received 2006-06-08
    Status Complete
    Date recommendation issued 2007-01-24
    Recommendation Do not list

    Submission status report

    Recommendation and reasons

  135. Escitalopram oxalate

    Brand name Cipralex
    Manufacturer Lundbeck Canada Inc.
    Indication(s) Depression, Major Depressive Disorder (MDD)
    Submission type Initial
    Project Number S0039
    Date submission received 2005-08-03
    Status Withdrawn
    Recommendation

    Submission status report

  136. Eslicarbazepine acetate

    Brand name Aptiom
    Manufacturer Sunovion Pharmaceuticals Canada Inc.
    Indication(s) Epilepsy, partial-onset seizures
    Submission type Initial
    Project Number SR0391
    Date submission received 2014-08-15
    Call for patient input 2014-07-17
    Patient input deadline 2014-09-08
    Status Active
    Recommendation

    Submission status report

  137. Etonogestrel / ethinyl estradiol

    Brand name NuvaRing
    Manufacturer Organon Canada Ltd.
    Indication(s) Contraceptive, ring
    Submission type Initial
    Project Number S0062
    Date submission received 2006-05-05
    Status Complete
    Date recommendation issued 2006-11-29
    Recommendation List with criteria/condition

    Submission status report

    Recommendation and reasons

  138. Etravirine

    Brand name Intelence
    Manufacturer Janssen-Ortho Inc.
    Indication(s) HIV
    Submission type Initial
    Project Number S0129
    Date submission received 2008-04-02
    Status Complete
    Date recommendation issued 2008-08-14
    Recommendation List with criteria/condition

    Submission status report

    Recommendation and reasons

  139. Everolimus

    Brand name Afinitor
    Manufacturer Novartis Pharmaceuticals Canada Inc.
    Indication(s) Subependymal giant cell astrocytoma associated with tuberous sclerosis complex
    Submission type New Indication
    Project Number SR0376-000
    Date submission received 2014-03-19
    Call for patient input 2014-07-09
    Patient input deadline 2014-08-28
    Status Active
    Recommendation

    Submission status report

  140. Everolimus

    Brand name Afinitor
    Manufacturer Novartis Pharmaceuticals Canada Inc.
    Indication(s) renal angiomyolipoma associated with tuberous sclerosis complex (TSC)
    Submission type Initial
    Project Number SR0315-000
    Date submission received 2013-03-08
    Call for patient input 2013-02-14
    Patient input deadline 2013-04-01
    Status Complete
    Date recommendation issued 2013-09-25
    Recommendation Do not list

    Submission status report

    Recommendation and reasons

  141. Exenatide

    Brand name Byetta
    Manufacturer Eli Lilly Canada
    Indication(s) Diabetes mellitus, Type 2
    Submission type Initial
    Project Number S0246
    Date submission received 2011-08-23
    Call for patient input 2011-08-09
    Patient input deadline 2011-09-14
    Status Complete
    Date recommendation issued 2012-07-19
    Recommendation Do not list

    Submission status report

    Recommendation and reasons

  142. Fampridine

    Brand name Fampyra
    Manufacturer Biogen Idec Canada Inc.
    Indication(s) Multiple Sclerosis, improve walking disability
    Submission type Resubmission #1
    Project Number SR0404-000
    Date submission received 2014-11-06
    Call for patient input 2014-09-03
    Patient input deadline 2014-10-23
    Status Active
    Recommendation

    Submission status report

  143. Fampridine

    Brand name Fampyra
    Manufacturer Biogen Idec Canada Inc.
    Indication(s) Multiple Sclerosis, improve walking disability
    Submission type Initial
    Project Number SR0275
    Date submission received 2012-04-16
    Call for patient input 2012-04-10
    Patient input deadline 2012-05-04
    Status Complete
    Date recommendation issued 2012-11-28
    Recommendation Do not list

    Submission status report

    Recommendation and reasons

  144. Febuxostat

    Brand name Uloric
    Manufacturer Takeda Canada Inc.
    Indication(s) Gout
    Submission type Initial
    Project Number S0213
    Date submission received 2010-10-27
    Call for patient input 2010-09-30
    Patient input deadline 2010-11-17
    Status Complete
    Date recommendation issued 2011-04-25
    Recommendation List with criteria/condition
    Plain language recommendation Plain language recommendation

    Submission status report

    Recommendation and reasons

  145. Fentanyl Citrate

    Brand name Onsolis
    Manufacturer Meda Valeant Pharma Canada Inc.
    Indication(s) Pain (breakthrough), cancer (adults)
    Submission type Resubmission #1
    Project Number S0248
    Date submission received 2011-08-22
    Status Complete
    Date recommendation issued 2012-02-15
    Recommendation Do not list
    Plain language recommendation Plain language recommendation

    Submission status report

    Recommendation and reasons

  146. Fentanyl citrate

    Brand name Abstral
    Manufacturer Paladin Labs Inc.
    Indication(s) Pain, Cancer (breakthrough)
    Submission type Initial
    Project Number S0240
    Date submission received 2011-06-30
    Call for patient input 2011-06-21
    Patient input deadline 2011-07-25
    Status Complete
    Date recommendation issued 2011-12-16
    Recommendation Do not list
    Plain language recommendation Plain language recommendation

    Submission status report

    Recommendation and reasons

  147. Fentanyl Citrate

    Brand name Onsolis
    Manufacturer Meda Valeant Pharma Canada Inc.
    Indication(s) Pain (breakthrough), cancer (adults)
    Submission type Initial
    Project Number S0229
    Date submission received 2011-05-10
    Call for patient input 2011-03-04
    Patient input deadline 2011-06-01
    Status Withdrawn
    Recommendation

    Submission status report

  148. Fesoterodine fumarate

    Brand name Toviaz
    Manufacturer Pfizer Canada Inc.
    Indication(s) Bladder, overactive
    Submission type Initial
    Project Number SR0277
    Date submission received 2012-04-27
    Call for patient input 2012-04-27
    Patient input deadline 2012-05-18
    Status Complete
    Date recommendation issued 2012-10-18
    Recommendation List in a similar manner

    Submission status report

    Recommendation and reasons

  149. Fidaxomicin

    Brand name Dificid
    Manufacturer Optimer Pharmaceuticals Canada, Inc.
    Indication(s) Clostridium difficile infection
    Submission type Initial
    Project Number SR0285
    Date submission received 2012-07-11
    Call for patient input 2012-06-27
    Patient input deadline 2012-08-01
    Status Complete
    Date recommendation issued 2012-12-19
    Recommendation Do not list at the submitted price

    Submission status report

    Recommendation and reasons

  150. Fingolimod

    Brand name Gilenya
    Manufacturer Novartis Pharmaceuticals Canada Inc.
    Indication(s) Multiple Sclerosis
    Submission type Initial
    Project Number S0228
    Date submission received 2011-05-10
    Call for patient input 2011-03-11
    Patient input deadline 2011-05-09
    Status Complete
    Date recommendation issued 2011-11-16
    Recommendation List with criteria/condition
    Plain language recommendation Plain language recommendation

    Submission status report

    Recommendation and reasons

  151. Fluticasone furoate / vilanterol

    Brand name Breo Ellipta
    Manufacturer GlaxoSmithKline
    Indication(s) Chronic Obstructive Pulmonary Disease (COPD)
    Submission type Initial
    Project Number SR0358
    Date submission received 2013-10-29
    Call for patient input 2013-10-01
    Patient input deadline 2013-11-19
    Status Active
    Date recommendation issued 2014-08-20
    Recommendation List with clinical criteria and/or conditions

    Submission status report

    Recommendation and reasons

  152. Fosamprenavir calcium

    Brand name Telzir
    Manufacturer GlaxoSmithKline Inc.
    Indication(s) HIV infection
    Submission type Initial
    Project Number S0030
    Date submission received 2005-01-24
    Status Complete
    Date recommendation issued 2005-06-16
    Recommendation List in a similar manner to other drugs in class

    Submission status report

    Recommendation and reasons

  153. Gefitinib

    Brand name Iressa
    Manufacturer AstraZeneca
    Indication(s) Cancer, Lung , non-small cell
    Submission type Initial
    Project Number S0003
    Date submission received 2003-12-22
    Status Complete
    Date recommendation issued 2004-06-23
    Recommendation Do not list

    Submission status report

    Recommendation and reasons

  154. Glatiramer acetate

    Brand name Copaxone
    Manufacturer Teva Pharmaceutical Industries Ltd.
    Indication(s) Clinically Isolated Syndrome (CIS), suggestive of Multiple Sclerosis
    Submission type New Indication
    Project Number S0164
    Date submission received 2009-04-29
    Status Complete
    Date recommendation issued 2009-11-25
    Recommendation Do not list

    Submission status report

    Recommendation and reasons

  155. Glycopyrronium bromide

    Brand name Seebri
    Manufacturer Novartis Pharmaceuticals Canada Inc.
    Indication(s) Chronic Obstructive Pulmonary Disease (COPD), maintenance bronchodilator treatment
    Submission type Initial
    Project Number SR0300
    Date submission received 2012-11-30
    Call for patient input 2012-11-27
    Patient input deadline 2012-12-21
    Status Complete
    Date recommendation issued 2013-05-15
    Recommendation List with clinical criteria and/or conditions

    Submission status report

    Recommendation and reasons

  156. Golimumab

    Brand name Simponi I.V.
    Manufacturer Janssen Inc.
    Indication(s) Arthritis, Rheumatoid
    Submission type Pre-NOC
    Project Number SR0351
    Date submission received 2013-09-12
    Call for patient input 2013-09-13
    Patient input deadline 2013-10-04
    Status Active
    Date recommendation issued 2014-07-17
    Recommendation List with clinical criteria and/or conditions

    Submission status report

    Recommendation and reasons

  157. Golimumab

    Brand name Simponi
    Manufacturer Janssen Inc.
    Indication(s) Ulcerative colitis
    Submission type Pre-NOC
    Project Number SR0341
    Date submission received 2013-07-12
    Call for patient input 2013-07-12
    Patient input deadline 2013-08-02
    Status Active
    Date recommendation issued 2014-03-19
    Recommendation Do not list at the submitted price

    Submission status report

    Clinical Report

    Pharmacoeconomic Report

    Recommendation and reasons

  158. Golimumab

    Brand name Simponi
    Manufacturer Centocor Inc.
    Indication(s) Arthritis, Rheumatoid
    Submission type Initial
    Project Number S0174
    Date submission received 2009-09-03
    Status Complete
    Date recommendation issued 2010-03-17
    Recommendation List in a similar manner

    Submission status report

    Recommendation and reasons

  159. Golimumab

    Brand name Simponi
    Manufacturer Centocor Inc.
    Indication(s) Arthritis, psoriatic
    Submission type Initial
    Project Number S0195
    Date submission received 2009-09-03
    Status Complete
    Date recommendation issued 2010-03-17
    Recommendation List in a similar manner

    Submission status report

    Recommendation and reasons

  160. Golimumab

    Brand name Simponi
    Manufacturer Centocor Inc.
    Indication(s) Ankylosing spondylitis
    Submission type Initial
    Project Number S0196
    Date submission received 2009-09-03
    Status Complete
    Date recommendation issued 2010-03-17
    Recommendation List in a similar manner

    Submission status report

    Recommendation and reasons

  161. Grass Pollen Allergen Extract

    Brand name Oralair
    Manufacturer Paladin Labs Inc.
    Indication(s) Allergic rhinitis (grass pollen)
    Submission type Initial
    Project Number SR0290
    Date submission received 2012-09-07
    Call for patient input 2012-09-07
    Patient input deadline 2012-10-15
    Status Complete
    Date recommendation issued 2013-03-20
    Recommendation List with clinical criteria and/or conditions

    Submission status report

    Recommendation and reasons

  162. Guanfacine hydrochloride

    Brand name Intuniv XR
    Manufacturer Shire Canada Inc.
    Indication(s) Attention-deficit/hyperactivity disorder (ADHD)
    Submission type Initial
    Project Number SR0349-000
    Date submission received 2013-08-27
    Call for patient input 2013-07-29
    Patient input deadline 2013-09-18
    Status Active
    Date recommendation issued 2014-09-24
    Recommendation Do not list

    Submission status report

    Recommendation and reasons

  163. Histrelin acetate

    Brand name Vantas
    Manufacturer Paladin Labs Inc.
    Indication(s) Cancer, prostate
    Submission type Initial
    Project Number S0078
    Date submission received 2006-09-20
    Status Complete
    Date recommendation issued 2007-04-26
    Recommendation Do not list

    Submission status report

    Recommendation and reasons

  164. Hydromorphone hydrochloride

    Brand name Jurnista
    Manufacturer Janssen-Ortho Inc.
    Indication(s) Pain, Chronic (moderate to severe)
    Submission type Initial
    Project Number S0190
    Date submission received 2009-12-04
    Status Complete
    Date recommendation issued 2010-05-19
    Recommendation Do not list

    Submission status report

    Recommendation and reasons

  165. Icatibant

    Brand name Firazyr
    Manufacturer Shire Human Genetic Therapies (Canada) Inc.
    Indication(s) Angioedema, hereditary
    Submission type Pre-NOC
    Project Number SR0375-000
    Date submission received 2014-03-04
    Call for patient input 2014-06-25
    Patient input deadline 2014-07-23
    Status Active
    Recommendation

    Submission status report

  166. Idursulfase

    Brand name Elaprase
    Manufacturer Shire Human Genetic Therapies, Inc.
    Indication(s) Mucopolysarccharidosis II (MPS II), Hunter Syndrome
    Submission type Initial
    Project Number S0104
    Date submission received 2007-07-13
    Status Complete
    Date recommendation issued 2007-12-19
    Recommendation Do not list

    Submission status report

    Recommendation and reasons

  167. Indacaterol

    Brand name Onbrez
    Manufacturer Novartis Pharmaceuticals Canada Inc.
    Indication(s) Chronic Obstructive Pulmonary Disease (COPD), maintenance bronchodilator treatment
    Submission type Initial
    Project Number SR0273
    Date submission received 2012-02-29
    Call for patient input 2012-02-15
    Patient input deadline 2012-03-20
    Status Complete
    Date recommendation issued 2012-08-16
    Recommendation List in a similar manner

    Submission status report

    Recommendation and reasons

  168. Indacaterol / glycopyrronium

    Brand name Ultibro Breezhaler
    Manufacturer Novartis Pharmaceuticals Canada Inc.
    Indication(s) COPD
    Submission type Initial
    Project Number SR0369-000
    Date submission received 2014-02-03
    Call for patient input 2014-06-25
    Patient input deadline 2014-07-23
    Status Active
    Recommendation

    Submission status report

  169. Infliximab

    Brand name Inflectra
    Manufacturer Hospira Healthcare Corporation
    Indication(s) Ankylosing spondylitis, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis
    Submission type Initial
    Project Number SE0384-000
    Date submission received 2014-06-17
    Call for patient input 2014-07-15
    Patient input deadline 2014-09-04
    Status Active
    Recommendation

    Submission status report

  170. Infliximab

    Brand name Remsima
    Manufacturer Fresenius Kabi Canada
    Indication(s) Ankylosing spondylitis, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis
    Submission type Initial
    Project Number SE0383-000
    Date submission received 2014-05-30
    Call for patient input 2014-07-15
    Patient input deadline 2014-09-04
    Status Withdrawn
    Recommendation

    Submission status report

  171. Infliximab

    Brand name Remicade
    Manufacturer Centocor Inc.
    Indication(s) Ulcerative Colitis
    Submission type Initial
    Project Number S0146
    Date submission received 2008-09-29
    Status Complete
    Date recommendation issued 2009-04-22
    Recommendation Do not list

    Submission status report

    Recommendation and reasons

  172. Ingenol mebutate

    Brand name Picato
    Manufacturer Leo Pharma Inc.
    Indication(s) Actinic keratosis
    Submission type Request for Advice
    Project Number SF0382-000
    Date submission received 2014-05-26
    Status Active
    Date recommendation issued 2014-10-22
    Recommendation Do not list

    Submission status report

    Record of Advice

  173. Ingenol mebutate

    Brand name Picato
    Manufacturer LEO Pharma Inc.
    Indication(s) Keratosis, actinic
    Submission type Initial
    Project Number SR0330
    Date submission received 2013-05-09 (Tentative)
    Call for patient input 2013-05-08
    Patient input deadline 2013-06-07
    Status Complete
    Date recommendation issued 2014-01-22
    Recommendation Do not list

    Submission status report

    Clinical Report

    Pharmacoeconomic Report

    Recommendation and reasons

  174. Insulin aspart / insulin aspart protamine

    Brand name NovoMix 30
    Manufacturer Novo Nordisk Canada Inc.
    Indication(s) Diabetes mellitus
    Submission type Initial
    Project Number S0041
    Date submission received 2005-10-13
    Status Complete
    Date recommendation issued 2006-04-26
    Recommendation Do not list

    Submission status report

    Recommendation and reasons

  175. Insulin detemir

    Brand name Levemir
    Manufacturer Novo Nordisk Canada Inc.
    Indication(s) Diabetes mellitus
    Submission type Resubmission #2
    Project Number S0160
    Date submission received 2009-03-10
    Status Complete
    Date recommendation issued 2009-08-20
    Recommendation Do not list

    Submission status report

    Recommendation and reasons

  176. Insulin detemir

    Brand name Levemir
    Manufacturer Novo Nordisk Canada Inc.
    Indication(s) Diabetes mellitus Type1, Pediatrics
    Submission type New Indication
    Project Number S0172
    Date submission received 2009-03-10
    Status Complete
    Date recommendation issued 2009-08-20
    Recommendation Do not list

    Submission status report

    Recommendation and reasons

  177. Insulin detemir

    Brand name Levemir
    Manufacturer Novo Nordisk Canada Inc.
    Indication(s) Diabetes mellitus
    Submission type Resubmission #1
    Project Number S0158
    Date submission received 2009-02-02
    Status Withdrawn
    Recommendation

    Submission status report

  178. Insulin detemir

    Brand name Levemir
    Manufacturer Novo Nordisk Canada Inc.
    Indication(s) Diabetes mellitus
    Submission type Initial
    Project Number S0049
    Date submission received 2005-12-19
    Status Complete
    Date recommendation issued 2006-08-02
    Recommendation Do not list

    Submission status report

    Recommendation and reasons

  179. Insulin glargine (rDNA origin)

    Brand name Lantus
    Manufacturer Sanofi-Aventis Canada Inc.
    Indication(s) Diabetes mellitus, Type 1 & 2
    Submission type Request for Advice
    Project Number S0166
    Date submission received 2009-06-09
    Status Complete
    Recommendation

    Submission status report

  180. Insulin glargine (rDNA origin)

    Brand name Lantus
    Manufacturer Sanofi-Aventis Canada Inc.
    Indication(s) Diabetes mellitus, Type 1 & 2
    Submission type Resubmission #1
    Project Number S0058
    Date submission received 2006-03-27
    Status Complete
    Date recommendation issued 2006-10-25
    Recommendation Do not list

    Submission status report

    Recommendation and reasons

  181. Insulin glargine (rDNA origin)

    Brand name Lantus
    Manufacturer Aventis Pharma Inc.
    Indication(s) Diabetes mellitus, Type 1 & 2
    Submission type Initial
    Project Number S0033
    Date submission received 2005-02-11
    Status Complete
    Date recommendation issued 2005-09-28
    Recommendation Do not list

    Submission status report

    Recommendation and reasons

  182. Insulin glulisine

    Brand name Apidra
    Manufacturer Sanofi-Aventis Canada Inc.
    Indication(s) Diabetes, Mellitus (Type 1 & 2)
    Submission type Initial
    Project Number S0144
    Date submission received 2008-08-29
    Status Complete
    Date recommendation issued 2009-02-19
    Recommendation List in a similar manner to other drugs in class

    Submission status report

    Recommendation and reasons

  183. Interferon beta-1a

    Brand name Rebif
    Manufacturer EMD Serono
    Indication(s) Clinically Isolated Syndrome
    Submission type Initial
    Project Number SR0298
    Date submission received 2013-03-08
    Call for patient input 2012-11-22
    Patient input deadline 2013-01-15
    Status Complete
    Date recommendation issued 2013-08-19
    Recommendation Do not list

    Submission status report

    Recommendation and reasons

  184. Ivacaftor

    Brand name Kalydeco
    Manufacturer Vertex Pharmaceuticals Canada
    Indication(s) Cystic Fibrosis (CFTR gating mutations)
    Submission type Pre-NOC
    Project Number SR0379-000
    Date submission received 2014-05-01
    Call for patient input 2014-06-25
    Patient input deadline 2014-07-23
    Status Active
    Recommendation

    Submission status report

  185. Ivacaftor

    Brand name Kalydeco
    Manufacturer Vertex Pharmaceuticals Inc.
    Indication(s) Cystic Fibrosis patients (G551D mutation)
    Submission type Pre-NOC
    Project Number SR0291
    Date submission received 2012-09-21
    Call for patient input 2012-09-21
    Patient input deadline 2012-10-22
    Status Complete
    Date recommendation issued 2013-03-22
    Recommendation List with clinical criteria and/or conditions

    Submission status report

    Recommendation and reasons

  186. Lacosamide

    Brand name Vimpat
    Manufacturer UCB Canada Inc.
    Indication(s) Epilepsy, partial onset seizures (POS)
    Submission type Initial
    Project Number S0212
    Date submission received 2010-10-25
    Call for patient input 2010-10-25
    Patient input deadline 2010-11-15
    Status Complete
    Date recommendation issued 2011-04-25
    Recommendation List with criteria/condition
    Plain language recommendation Plain language recommendation

    Submission status report

    Recommendation and reasons

  187. Lanreotide acetate

    Brand name Somatuline Autogel
    Manufacturer Ipsen Limited
    Indication(s) Acromegaly
    Submission type Initial
    Project Number S0091
    Date submission received 2007-02-20
    Status Complete
    Date recommendation issued 2007-07-19
    Recommendation List in a similar manner to other drugs in class

    Submission status report

    Recommendation and reasons

  188. Lanthanum carbonate hydrate

    Brand name Fosrenol
    Manufacturer Shire BioChem Inc.
    Indication(s) Hyperphosphatemia, end-stage renal disease
    Submission type Initial
    Project Number S0100
    Date submission received 2007-06-28
    Status Complete
    Date recommendation issued 2008-01-30
    Recommendation Do not list

    Submission status report

    Recommendation and reasons

  189. Laronidase

    Brand name Aldurazyme
    Manufacturer Genzyme Canada
    Indication(s) Mucopolysarccharidosis 1 (MPS 1), Hurler, Hurler-Scheie, Scheie
    Submission type Initial
    Project Number S0032
    Date submission received 2005-02-03
    Status Complete
    Date recommendation issued 2005-07-14
    Recommendation Do not list

    Submission status report

    Recommendation and reasons

  190. Ledipasvir / Sofosbuvir

    Brand name Harvoni
    Manufacturer Gilead Sciences Canada Inc.
    Indication(s) Hepatitis C, chronic
    Submission type Initial
    Project Number SR0395
    Date submission received 2014-09-15
    Call for patient input 2014-08-18
    Patient input deadline 2014-10-07
    Status Active
    Recommendation

    Submission status report

  191. Levodopa / carbidopa

    Brand name Duodopa
    Manufacturer Solvay Pharma Inc.
    Indication(s) Parkinson's disease
    Submission type Initial
    Project Number S0154
    Date submission received 2008-12-19
    Status Complete
    Date recommendation issued 2009-07-22
    Recommendation Do not list

    Submission status report

    Recommendation and reasons

  192. Linaclotide

    Brand name Constella
    Manufacturer Actavis Specialty Pharmaceuticals Co.
    Indication(s) Irritable bowel syndrome with constipation
    Submission type Initial
    Project Number SR0409
    Date submission received 2014-12-17
    Call for patient input 2014-10-22
    Patient input deadline 2014-12-10
    Status Received
    Recommendation

    Submission status report

  193. Linagliptin

    Brand name Trajenta
    Manufacturer Boehringer Ingelheim Canada
    Indication(s) Diabetes mellitus, Type 2
    Submission type Initial
    Project Number S0244
    Date submission received 2011-08-23
    Call for patient input 2011-08-09
    Patient input deadline 2011-09-14
    Status Complete
    Date recommendation issued 2012-02-15
    Recommendation List with criteria/condition

    Submission status report

    Recommendation and reasons

  194. Linagliptin-metformin

    Brand name Jentadueto
    Manufacturer Boehringer Ingelheim (Canada) Ltd.
    Indication(s) Diabetes mellitus (Type 2)
    Submission type Initial
    Project Number SR0306
    Date submission received 2013-03-08
    Call for patient input 2013-01-10
    Patient input deadline 2013-03-01
    Status Complete
    Date recommendation issued 2013-10-17
    Recommendation List with clinical criteria and/or conditions

    Submission status report

    Recommendation and reasons

  195. Liraglutide

    Brand name Victoza
    Manufacturer Novo Nordisk Canada Inc.
    Indication(s) Diabetes mellitus, Type 2
    Submission type Initial
    Project Number S0217
    Date submission received 2010-11-29
    Call for patient input 2010-10-12
    Patient input deadline 2011-01-10
    Status Complete
    Date recommendation issued 2011-09-28
    Recommendation Do not list
    Plain language recommendation Plain language recommendation

    Submission status report

    Recommendation and reasons

  196. Lisdexamfetamine dimesylate

    Brand name Vyvanse
    Manufacturer Shire Canada Inc.
    Indication(s) Attention deficit hyperactivity disorder
    Submission type Initial
    Project Number S0171
    Date submission received 2009-07-10
    Status Complete
    Date recommendation issued 2009-12-18
    Recommendation Do not list

    Submission status report

    Recommendation and reasons

  197. Lomitapide

    Brand name Juxtapid
    Manufacturer Aegerion Pharmaceuticals (Canada) Ltd.
    Indication(s) Hypercholesterolemia, Homozygous Familial
    Submission type Initial
    Project Number SR0386-000
    Date submission received 2014-07-08
    Call for patient input 2014-07-09
    Patient input deadline 2014-08-28
    Status Active
    Recommendation

    Submission status report

  198. Loteprednol etabonate

    Brand name Lotemax
    Manufacturer Bausch & Lomb
    Indication(s) Post-operative inflammation following cataract surgery
    Submission type Initial
    Project Number S0186
    Date submission received 2009-12-02
    Status Complete
    Date recommendation issued 2010-05-19
    Recommendation Do not list

    Submission status report

    Recommendation and reasons

  199. Lumiracoxib

    Brand name Prexige
    Manufacturer Novartis Pharmaceuticals Canada Inc.
    Indication(s) Osteoarthritis (Knee)
    Submission type Initial
    Project Number S0090
    Date submission received 2006-12-15
    Status Complete
    Date recommendation issued 2007-07-25
    Recommendation Do not list

    Submission status report

    Recommendation and reasons

  200. Lurasidone

    Brand name Latuda
    Manufacturer Sunovion Pharmaceuticals Inc.
    Indication(s) Schizophrenia
    Submission type Resubmission #1
    Project Number SR0331
    Date submission received 2013-05-09
    Call for patient input 2013-05-09
    Patient input deadline 2013-05-31
    Status Complete
    Date recommendation issued 2013-12-20
    Recommendation List with clinical criteria and/or conditions

    Submission status report

    Clinical Report

    Pharmacoeconomic Report

    Recommendation and reasons

  201. Lurasidone

    Brand name Latuda
    Manufacturer Sunovion Pharmaceuticals Inc.
    Indication(s) schizophrenia
    Submission type Initial
    Project Number SR0284
    Date submission received 2012-07-03
    Call for patient input 2012-06-20
    Patient input deadline 2012-07-24
    Status Complete
    Date recommendation issued 2013-01-23
    Recommendation Do not list

    Submission status report

    Recommendation and reasons

  202. Macitentan

    Brand name Opsumit
    Manufacturer Actelion Pharmaceuticals Canada Inc.
    Indication(s) Pulmonary arterial hypertension
    Submission type Initial
    Project Number SR0364
    Date submission received 2013-12-16
    Call for patient input 2014-04-30
    Patient input deadline 2014-06-19
    Status Active
    Recommendation

    Submission status report

  203. Maraviroc

    Brand name Celsentri
    Manufacturer GlaxoSmithKline
    Indication(s) HIV-1, treatment naïve (adult)
    Submission type New Indication
    Project Number S0221
    Date submission received 2010-12-08
    Call for patient input 2010-12-09
    Patient input deadline 2011-01-31
    Status Complete
    Date recommendation issued 2011-07-18
    Recommendation Do not list
    Plain language recommendation Plain language recommendation

    Submission status report

    Recommendation and reasons

  204. Maraviroc

    Brand name Celsentri
    Manufacturer Pfizer Canada Inc.
    Indication(s) HIV
    Submission type Resubmission #1
    Project Number S0136
    Date submission received 2008-05-07
    Status Complete
    Date recommendation issued 2008-11-12
    Recommendation List with criteria/condition

    Submission status report

    Recommendation and reasons

  205. Maraviroc

    Brand name Celsentri
    Manufacturer Pfizer Canada Inc.
    Indication(s) HIV
    Submission type Initial
    Project Number S0113
    Date submission received 2007-11-02
    Status Withdrawn
    Recommendation

    Submission status report

  206. Memantine hydrochloride

    Brand name Ebixa
    Manufacturer Lundbeck Canada Inc.
    Indication(s) Dementia (Alzheimer type), moderate to severe
    Submission type Initial
    Project Number S0025
    Date submission received 2004-12-21
    Status Complete
    Date recommendation issued 2005-11-23
    Recommendation Do not list

    Submission status report

    Recommendation and reasons

  207. Methylnaltrexone bromide

    Brand name Relistor
    Manufacturer Wyeth Canada
    Indication(s) Constipation, Opioid-induced
    Submission type Initial
    Project Number S0135
    Date submission received 2008-05-07
    Status Complete
    Date recommendation issued 2009-01-28
    Recommendation Do not list

    Submission status report

    Recommendation and reasons

  208. Miglustat

    Brand name Zavesca
    Manufacturer Actelion Pharmaceuticals Canada Inc.
    Indication(s) Gaucher disease
    Submission type Initial
    Project Number S0012
    Date submission received 2004-05-13
    Status Complete
    Date recommendation issued 2004-11-24
    Recommendation Do not list

    Submission status report

    Recommendation and reasons

  209. Mirabegron

    Brand name Myrbetriq
    Manufacturer Astellas Pharma Canada Inc.
    Indication(s) Bladder, overactive
    Submission type Initial
    Project Number SR0363
    Date submission received 2013-11-27
    Call for patient input 2014-04-24
    Patient input deadline 2014-06-13
    Status Active
    Date recommendation issued 2014-11-12
    Recommendation List with clinical criteria and/or conditions

    Submission status report

    Recommendation and reasons

  210. Mirabegron

    Brand name Myrbetriq
    Manufacturer Astellas Pharma Canada, Inc.
    Indication(s) Bladder, Overactive
    Submission type Initial
    Project Number SR0319
    Date submission received 2013-03-08
    Call for patient input 2013-03-08
    Patient input deadline 2013-04-01
    Status Withdrawn
    Recommendation

    Submission status report

  211. Mixed amphetamine salts

    Brand name Adderall XR
    Manufacturer Shire Canada Inc.
    Indication(s) Attention deficit hyperactivity disorder, Adult
    Submission type New Indication
    Project Number S0116
    Date submission received 2007-11-29
    Status Complete
    Date recommendation issued 2008-06-25
    Recommendation Do not list
    Plain language recommendation Plain language recommendation
    Summary of CEDAC Discussion Summary of CEDAC Discussion
    Overview of CDR reports Overview of CDR reports

    Submission status report

    Recommendation and reasons

  212. Mixed amphetamine salts

    Brand name Adderall XR
    Manufacturer Shire BioChem Inc.
    Indication(s) Attention deficit hyperactivity disorder
    Submission type Resubmission #1
    Project Number S0027
    Date submission received 2004-12-15
    Status Withdrawn
    Recommendation

    Submission status report

  213. Mixed amphetamine salts

    Brand name Adderall XR
    Manufacturer Shire BioChem Inc.
    Indication(s) Attention deficit hyperactivity disorder
    Submission type Initial
    Project Number S0010
    Date submission received 2004-04-13
    Status Complete
    Date recommendation issued 2004-11-24
    Recommendation Do not list

    Submission status report

    Recommendation and reasons

  214. Mometasone furoate

    Brand name ASMANEX
    Manufacturer Merck Canada Inc.
    Indication(s) Asthma, (Bronchial) Prophylactic management of steroid responsive
    Submission type Initial
    Project Number SR0258
    Date submission received 2011-11-10
    Call for patient input 2011-11-17
    Patient input deadline 2011-11-21
    Status Complete
    Date recommendation issued 2012-05-16
    Recommendation List

    Submission status report

    Recommendation and reasons

  215. Mometasone furoate and formoterol

    Brand name Zenhale (inhalation aerosol)
    Manufacturer Merck Canada
    Indication(s) Asthma maintenance (adults, children 12 or older)
    Submission type Initial
    Project Number S0225
    Date submission received 2011-02-16
    Call for patient input 2011-01-31
    Patient input deadline 2011-03-10
    Status Complete
    Date recommendation issued 2011-09-28
    Recommendation Do not list
    Plain language recommendation Plain language recommendation

    Submission status report

    Recommendation and reasons

  216. Mometasone / formoterol

    Brand name Zenhale
    Manufacturer Merck Canada Inc.
    Indication(s) Asthma maintenance (adults, children 12 or older)
    Submission type Request for Advice
    Project Number S0281
    Date submission received 2012-06-06
    Status Complete
    Date recommendation issued 2012-12-19
    Recommendation List with criteria/condition

    Submission status report

    Recommendation and reasons

  217. Mycophenolate sodium

    Brand name Myfortic
    Manufacturer Novartis Pharmaceuticals Canada Inc.
    Indication(s) Organ rejection in allogeneic renal transplants, Prophylaxis
    Submission type Initial
    Project Number S0034
    Date submission received 2005-03-03
    Status Complete
    Date recommendation issued 2005-07-08
    Recommendation List in a similar manner to other drugs in class

    Submission status report

    Recommendation and reasons

  218. Natalizumab

    Brand name Tysabri
    Manufacturer Biogen Idec Canada Inc.
    Indication(s) Multiple Sclerosis, relapsing-remitting
    Submission type Resubmission #1
    Project Number S0133
    Date submission received 2008-05-06
    Status Complete
    Date recommendation issued 2009-02-25
    Recommendation List with criteria/condition

    Submission status report

    Recommendation and reasons

  219. Natalizumab

    Brand name Tysabri
    Manufacturer Biogen Idec Canada Inc.
    Indication(s) Multiple Sclerosis, relapsing-remitting
    Submission type Initial
    Project Number S0082
    Date submission received 2006-10-26
    Status Complete
    Date recommendation issued 2007-04-26
    Recommendation Do not list

    Submission status report

    Recommendation and reasons

  220. Nebivolol

    Brand name Bystolic
    Manufacturer Forest Laboratories Canada Inc.
    Indication(s) Hypertension, essential
    Submission type Initial
    Project Number SR0307
    Date submission received 2013-02-04
    Call for patient input 2013-01-16
    Patient input deadline 2013-03-04
    Status Complete
    Date recommendation issued 2013-07-18
    Recommendation Do not list at the submitted price

    Submission status report

    Recommendation and reasons

  221. Niacin / lovastatin

    Brand name Advicor
    Manufacturer Oryx Pharmaceuticals Inc.
    Indication(s) Hypercholesterolemia and mixed dyslipidemia
    Submission type Initial
    Project Number S0042
    Date submission received 2005-10-18
    Status Complete
    Date recommendation issued 2006-04-26
    Recommendation List

    Submission status report

    Recommendation and reasons

  222. Norgelestromin / ethinyl estradiol

    Brand name Evra
    Manufacturer Janssen-Ortho Inc.
    Indication(s) Contraceptive, patch
    Submission type Initial
    Project Number S0004
    Date submission received 2003-12-19
    Status Complete
    Date recommendation issued 2004-06-23
    Recommendation Do not list

    Submission status report

    Recommendation and reasons

  223. Ocriplasmin

    Brand name Jetrea
    Manufacturer Alcon Canada Inc.
    Indication(s) Vitreomacular adhesion
    Submission type Pre-NOC
    Project Number SR0337
    Date submission received 2013-06-06
    Call for patient input 2013-06-06
    Patient input deadline 2013-06-27
    Status Complete
    Date recommendation issued 2013-12-20
    Recommendation List with clinical criteria and/or conditions

    Submission status report

    Clinical Report

    Pharmacoeconomic Report

    Recommendation and reasons

  224. Olmesartan medoxomil

    Brand name Olmetec
    Manufacturer Schering-Plough Canada Inc.
    Indication(s) Hypertension
    Submission type Initial
    Project Number S0150
    Date submission received 2008-11-28
    Status Complete
    Date recommendation issued 2009-05-27
    Recommendation List in a similar manner to other drugs in class

    Submission status report

    Recommendation and reasons

  225. Olmesartan medoxomil + hydrochlorothiazide

    Brand name Olmetec Plus
    Manufacturer Schering-Plough Canada Inc.
    Indication(s) Hypertension
    Submission type Initial
    Project Number S0151
    Date submission received 2008-11-28
    Status Complete
    Date recommendation issued 2009-05-27
    Recommendation List in a similar manner to other drugs in class

    Submission status report

    Recommendation and reasons

  226. Omalizumab

    Brand name Xolair
    Manufacturer Novartis Pharmaceuticals Canada Inc.
    Indication(s) Urticaria, chronic idiopathic
    Submission type New Indication
    Project Number SR0398
    Date submission received 2014-09-22
    Call for patient input 2014-08-22
    Patient input deadline 2014-10-14
    Status Active
    Recommendation

    Submission status report

  227. Omalizumab

    Brand name Xolair
    Manufacturer Novartis Pharmaceuticals Canada Inc.
    Indication(s) Asthma, severe persistent
    Submission type Resubmission #1
    Project Number S0045
    Date submission received 2005-10-13
    Status Complete
    Date recommendation issued 2006-03-07
    Recommendation Do not list

    Submission status report

    Recommendation and reasons

  228. Omalizumab

    Brand name Xolair
    Manufacturer Novartis Pharmaceuticals Canada Inc.
    Indication(s) Asthma, severe persistent
    Submission type Initial
    Project Number S0035
    Date submission received 2005-04-18
    Status Suspended
    Recommendation

    Submission status report

  229. Ombitasvir / paritaprevir / ritonavir and dasabuvir

    Brand name TBC
    Manufacturer AbbVie Corporation
    Indication(s) Hepatitis C, chronic
    Submission type Initial
    Project Number SR0406-000
    Date submission received 2014-12-03
    Call for patient input 2014-11-03
    Patient input deadline 2014-12-22
    Status Queued
    Recommendation

    Submit Patient Input


    Submission status report

  230. OnabotulinumtoxinA

    Brand name Botox
    Manufacturer Allergan Inc.
    Indication(s) Urinary incontinence
    Submission type New Indication
    Project Number SR0362
    Date submission received 2013-11-25
    Call for patient input 2014-04-10
    Patient input deadline 2014-06-02
    Status Active
    Date recommendation issued 2014-11-12
    Recommendation List with clinical criteria and/or conditions

    Submission status report

    Recommendation and reasons

  231. OnabotulinumtoxinA

    Brand name Botox
    Manufacturer Allergan Inc.
    Indication(s) Migraine, chronic
    Submission type New Indication
    Project Number SR0345
    Date submission received 2013-08-15
    Call for patient input 2013-07-12
    Patient input deadline 2013-09-03
    Status Active
    Date recommendation issued 2014-05-28
    Recommendation Do not list

    Submission status report

    Recommendation and reasons

  232. OnabotulinumtoxinA

    Brand name Botox
    Manufacturer Allergan Inc.
    Indication(s) Neurogenic Detrusor Overactivity
    Submission type Initial
    Project Number SR0268
    Date submission received 2012-01-31
    Call for patient input 2012-01-23
    Patient input deadline 2012-02-17
    Status Complete
    Date recommendation issued 2012-07-19
    Recommendation List with criteria/condition

    Submission status report

    Recommendation and reasons

  233. Oxybutynin Chloride Gel

    Brand name GELNIQUE
    Manufacturer Watson Pharma Company
    Indication(s) Bladder, overactive
    Submission type Initial
    Project Number S0260
    Date submission received 2011-10-25
    Call for patient input 2011-10-13
    Patient input deadline 2011-11-17
    Status Complete
    Date recommendation issued 2012-05-24
    Recommendation Do not list

    Submission status report

    Recommendation and reasons

  234. Oxycodone / naloxone

    Brand name Targin
    Manufacturer Purdue Pharma
    Indication(s) Pain, Moderate to severe and relief of opioid-induced constipation
    Submission type Initial
    Project Number S0219
    Date submission received 2010-11-30
    Call for patient input 2010-12-02
    Patient input deadline 2011-01-21
    Status Stopped
    Recommendation

    Submission status report

  235. Oxycodone HCI / naloxone HCI

    Brand name Targin
    Manufacturer Purdue Pharma
    Indication(s) Pain, Moderate to severe and relief of opioid-induced constipation
    Submission type Resubmission #1
    Project Number S0241
    Date submission received 2011-07-05
    Status Complete
    Date recommendation issued 2012-01-25
    Recommendation Do not list

    Submission status report

    Recommendation and reasons

  236. Paliperidone

    Brand name Invega
    Manufacturer Janssen-Ortho Inc.
    Indication(s) Schizophrenia
    Submission type Initial
    Project Number S0112
    Date submission received 2007-11-01
    Status Complete
    Date recommendation issued 2008-05-28
    Recommendation Do not list

    Submission status report

    Recommendation and reasons

  237. Paliperidone palmitate

    Brand name Invega Sustenna
    Manufacturer Janssen-Ortho Inc.
    Indication(s) Schizophrenia
    Submission type Initial
    Project Number S0206
    Date submission received 2010-07-09
    Call for patient input 2010-06-22
    Patient input deadline 2010-07-30
    Status Complete
    Date recommendation issued 2011-04-25
    Recommendation Do not list
    Plain language recommendation Plain language recommendation

    Submission status report

    Recommendation and reasons

  238. Palonosetron hydrochloride

    Brand name Aloxi (injection)
    Manufacturer Eisai Ltd.
    Indication(s) Nausea and vomiting (chemotherapy induced) prevention
    Submission type Initial
    Project Number SR0293
    Date submission received 2012-10-05
    Call for patient input 2012-10-05
    Patient input deadline 2012-10-26
    Status Complete
    Date recommendation issued 2013-05-15
    Recommendation Do not list at the submitted price

    Submission status report

    Recommendation and reasons

  239. Palonosetron hydrochloride

    Brand name Aloxi (capsule)
    Manufacturer Eisai Ltd.
    Indication(s) Nausea and vomiting (chemotherapy induced) prevention
    Submission type Initial
    Project Number SR0294
    Date submission received 2012-10-05
    Call for patient input 2012-10-05
    Patient input deadline 2012-10-26
    Status Complete
    Date recommendation issued 2013-04-24
    Recommendation Do not list

    Submission status report

    Recommendation and reasons

  240. Pantoprazole magnesium

    Brand name Pantoloc M
    Manufacturer Altana Pharma Inc.
    Indication(s) Gastric acid secretion, reduction of
    Submission type Initial
    Project Number S0054
    Date submission received 2006-03-17
    Status Complete
    Date recommendation issued 2006-07-20
    Recommendation List in a similar manner to other drugs in class

    Submission status report

    Recommendation and reasons

  241. Pasireotide

    Brand name Signifor LAR
    Manufacturer Novartis
    Indication(s) Acromegaly
    Submission type Initial
    Project Number TBC
    Date submission received 2015-03-15 (Tentative)
    Status Pending
    Recommendation
  242. Pasireotide

    Brand name Signifor
    Manufacturer Novartis Pharmaceuticals Inc.
    Indication(s) Cushing’s Disease
    Submission type Initial
    Project Number SR0372-000
    Date submission received 2014-02-27
    Call for patient input 2014-07-09
    Patient input deadline 2014-08-28
    Status Active
    Recommendation

    Submission status report

  243. Pegaptanib sodium

    Brand name Macugen
    Manufacturer Pfizer Canada Inc.
    Indication(s) Macular degeneration, age-related
    Submission type Initial
    Project Number S0044
    Date submission received 2005-10-20
    Status Complete
    Date recommendation issued 2006-05-25
    Recommendation Do not list

    Submission status report

    Recommendation and reasons

  244. Pegfilgrastim

    Brand name Neulasta
    Manufacturer Amgen Canada Inc.
    Indication(s) Neutropenia
    Submission type Initial
    Project Number S0009
    Date submission received 2004-03-29
    Status Complete
    Date recommendation issued 2004-10-27
    Recommendation List with criteria/condition

    Submission status report

    Recommendation and reasons

  245. Peginterferon alfa-2a and Ribavirin

    Brand name Pegasys RBV
    Manufacturer Hoffman-La Roche Ltd.
    Indication(s) Hepatitis C, chronic
    Submission type Initial
    Project Number S0013
    Date submission received 2004-05-14
    Status Complete
    Date recommendation issued 2004-10-14
    Recommendation List in a similar manner to other drugs in class

    Submission status report

    Recommendation and reasons

  246. Pegvisomant

    Brand name Somavert
    Manufacturer Pfizer Canada Inc.
    Indication(s) acromegaly
    Submission type Initial
    Project Number S0050
    Date submission received 2006-01-25
    Status Complete
    Date recommendation issued 2006-08-02
    Recommendation Do not list

    Submission status report

    Recommendation and reasons

  247. Penciclovir

    Brand name Denavir
    Manufacturer Novartis Consumer Health Care Inc.
    Indication(s) Herpes labialis (cold sores)
    Submission type Initial
    Project Number S0075
    Date submission received 2006-09-20
    Status Complete
    Date recommendation issued 2007-04-26
    Recommendation Do not list

    Submission status report

    Recommendation and reasons

  248. Perampanel

    Brand name Fycompa
    Manufacturer Eisai Ltd.
    Indication(s) Epilepsy, partial onset seizures
    Submission type Pre-NOC
    Project Number SR0316-000
    Date submission received 2013-03-08
    Call for patient input 2013-02-21
    Patient input deadline 2013-04-01
    Status Complete
    Date recommendation issued 2013-10-17
    Recommendation List with clinical criteria and/or conditions

    Submission status report

    Recommendation and reasons

  249. Phleum pratense

    Brand name Grastek
    Manufacturer Merck Canada Inc.
    Indication(s) Allergy (grass)
    Submission type Pre-NOC
    Project Number SR0352
    Date submission received 2013-09-30
    Call for patient input 2013-08-19
    Patient input deadline 2013-10-07
    Status Active
    Date recommendation issued 2014-09-24
    Recommendation Do not list

    Submission status report

    Clinical Report

    Pharmacoeconomic Report

    Recommendation and reasons

  250. Pirfenidone

    Brand name Esbriet
    Manufacturer InterMune Canada Inc.
    Indication(s) Pulmonary fibrosis (idiopathic, mild to moderate)
    Submission type Resubmission #1
    Project Number SR0393
    Date submission received 2014-08-29
    Call for patient input 2014-07-31
    Patient input deadline 2014-09-22
    Status Active
    Recommendation

    Submission status report

  251. Pirfenidone

    Brand name Esbriet
    Manufacturer InterMune Canada Inc.
    Indication(s) Pulmonary fibrosis (idiopathic, mild to moderate)
    Submission type Initial
    Project Number SR0292
    Date submission received 2012-10-05
    Call for patient input 2012-10-05
    Patient input deadline 2012-10-26
    Status Complete
    Date recommendation issued 2013-04-18
    Recommendation Do not list

    Submission status report

    Recommendation and reasons

  252. Plerixafor

    Brand name Mozobil
    Manufacturer Genzyme Canada Inc.
    Indication(s) Hematopoietic stem cell mobilizer in non-Hodgkin's lymphoma and multiple myeloma
    Submission type Initial
    Project Number SR0265
    Date submission received 2012-01-24
    Call for patient input 2012-01-26
    Patient input deadline 2012-02-15
    Status Complete
    Date recommendation issued 2012-09-26
    Recommendation Do not list

    Submission status report

    Recommendation and reasons

  253. Posaconazole

    Brand name Spriafil
    Manufacturer Schering-Plough Canada Inc.
    Indication(s) Aspergillus and Candida infections
    Submission type Initial
    Project Number S0097
    Date submission received 2007-05-24
    Status Complete
    Date recommendation issued 2008-01-30
    Recommendation Do not list

    Submission status report

    Recommendation and reasons

  254. Prasugrel

    Brand name Effient
    Manufacturer Eli Lily Canada Inc.
    Indication(s) Acute Coronary Syndrome (ACS)
    Submission type Resubmission #1
    Project Number S0263
    Date submission received 2011-12-12
    Call for patient input 2011-12-16
    Patient input deadline 2012-01-16
    Status Complete
    Date recommendation issued 2012-06-14
    Recommendation Do not list

    Submission status report

    Recommendation and reasons

  255. Prasugrel hydrochloride

    Brand name Effient
    Manufacturer Eli Lilly Canada Inc.
    Indication(s) Acute Coronary Syndrome (ACS)
    Submission type Initial
    Project Number S0200
    Date submission received 2010-05-05
    Status Complete
    Date recommendation issued 2011-02-16
    Recommendation Do not list

    Submission status report

    Recommendation and reasons

  256. Pregabalin

    Brand name Lyrica
    Manufacturer Pfizer Canada Inc.
    Indication(s) diabetic peripheral neuropathy
    Submission type Resubmission #1
    Project Number S0162
    Date submission received 2009-03-20
    Status Complete
    Date recommendation issued 2009-09-23
    Recommendation Do not list

    Submission status report

    Recommendation and reasons

  257. Pregabalin

    Brand name Lyrica
    Manufacturer Pfizer Canada Inc.
    Indication(s) Pain, Neuropathic
    Submission type Initial
    Project Number S0036
    Date submission received 2005-06-27
    Status Complete
    Date recommendation issued 2006-01-25
    Recommendation Do not list

    Submission status report

    Recommendation and reasons

  258. Propranolol

    Brand name Hemangiol
    Manufacturer Pierre Fabre Dermo-Cosmétique Canada Inc.
    Indication(s) Infantile hemangioma
    Submission type Pre-NOC
    Project Number TBC
    Date submission received 2015-01-05 (Tentative)
    Call for patient input 2014-12-01
    Patient input deadline 2015-01-27
    Status Pending
    Recommendation

    Submit Patient Input


  259. Prucalopride

    Brand name Resotran
    Manufacturer Janssen Inc.
    Indication(s) Constipation, chronic
    Submission type Initial
    Project Number SR0266
    Date submission received 2012-01-31
    Call for patient input 2012-01-17
    Patient input deadline 2012-02-22
    Status Complete
    Date recommendation issued 2012-07-19
    Recommendation Do not list

    Submission status report

    Recommendation and reasons

  260. Quinagolide hydrochloride

    Brand name Norprolac
    Manufacturer Ferring Pharmaceuticals
    Indication(s) Hyperprolactinemia
    Submission type Resubmission #1
    Project Number S0046
    Date submission received 2005-11-23
    Status Complete
    Date recommendation issued 2006-05-17
    Recommendation List with criteria/condition

    Submission status report

    Recommendation and reasons

  261. Quinagolide hydrochloride

    Brand name Norprolac
    Manufacturer Ferring Pharmaceuticals
    Indication(s) Hyperprolactinemia
    Submission type Initial
    Project Number S0026
    Date submission received 2004-12-16
    Status Complete
    Date recommendation issued 2005-09-28
    Recommendation Do not list

    Submission status report

    Recommendation and reasons

  262. Raltegravir

    Brand name Isentress
    Manufacturer Merck Frosst Canada Ltd.
    Indication(s) HIV (treatment naïve)
    Submission type New Indication
    Project Number S0191
    Date submission received 2009-12-04
    Status Complete
    Date recommendation issued 2010-06-23
    Recommendation Do not list

    Submission status report

    Recommendation and reasons

  263. Raltegravir

    Brand name Isentress
    Manufacturer Merck Frosst Canada Ltd.
    Indication(s) HIV
    Submission type Initial
    Project Number S0115
    Date submission received 2007-11-29
    Status Complete
    Date recommendation issued 2008-05-14
    Recommendation List with criteria/condition
    Plain language recommendation Plain language recommendation
    Summary of CEDAC Discussion Summary of CEDAC Discussion
    Overview of CDR reports Overview of CDR reports

    Submission status report

    Recommendation and reasons

  264. Ramipril / felodipine extended release

    Brand name Altace Plus Felodipine
    Manufacturer Sanofi-Aventis Canada Inc.
    Indication(s) Hypertension
    Submission type Initial
    Project Number S0067
    Date submission received 2006-06-22
    Status Complete
    Date recommendation issued 2006-11-15
    Recommendation Do not list

    Submission status report

    Recommendation and reasons

  265. Ramipril / hydrochlorothiazide

    Brand name Altace HCT
    Manufacturer Sanofi-Aventis Canada Inc.
    Indication(s) Hypertension
    Submission type Resubmission #1
    Project Number S0095
    Date submission received 2007-03-26
    Status Complete
    Date recommendation issued 2007-06-14
    Recommendation List

    Submission status report

    Recommendation and reasons

  266. Ramipril / hydrochlorothiazide

    Brand name Altace HCT
    Manufacturer Sanofi –Aventis Canada inc.
    Indication(s) Hypertension
    Submission type Initial
    Project Number S0083
    Date submission received 2006-10-26
    Status Suspended
    Recommendation

    Submission status report

  267. Ranibizumab

    Brand name Lucentis
    Manufacturer Novartis Pharmaceuticals Canada Inc.
    Indication(s) Choroidal neovascularisation, myopic
    Submission type Initial
    Project Number SR0373-000
    Date submission received 2014-02-28
    Call for patient input 2014-07-09
    Patient input deadline 2014-08-28
    Status Active
    Recommendation

    Submission status report

  268. Ranibizumab

    Brand name Lucentis
    Manufacturer Novartis Pharmaceuticals Canada Inc.
    Indication(s) Macular edema, diabetic
    Submission type New Indication
    Project Number S0253
    Date submission received 2011-09-14
    Call for patient input 2011-08-31
    Patient input deadline 2011-10-05
    Status Complete
    Date recommendation issued 2012-03-19
    Recommendation List with criteria/condition

    Submission status report

    Recommendation and reasons

  269. Ranibizumab

    Brand name Lucentis
    Manufacturer Novartis Pharmaceuticals Inc.
    Indication(s) Macular degeneration, age-related
    Submission type Initial
    Project Number S0098
    Date submission received 2007-07-12
    Status Complete
    Date recommendation issued 2008-03-27
    Recommendation List with criteria/condition
    Plain language recommendation Plain language recommendation
    Summary of CEDAC Discussion Summary of CEDAC Discussion
    Overview of CDR reports Overview of CDR reports

    Submission status report

    Recommendation and reasons

  270. Ranibizumab injection

    Brand name Lucentis
    Manufacturer Novartis Pharmaceuticals Canada Inc.
    Indication(s) Macular edema, secondary to retinal vein occlusion
    Submission type Initial
    Project Number SR0276
    Date submission received 2012-04-25
    Call for patient input 2012-04-11
    Patient input deadline 2012-05-16
    Status Complete
    Date recommendation issued 2012-10-18
    Recommendation List with criteria/condition

    Submission status report

    Recommendation and reasons

  271. Rasagiline mesylate

    Brand name Azilect
    Manufacturer Teva Pharmaceuticals Industries Ltd.
    Indication(s) Parkinson’s disease
    Submission type Request for Advice
    Project Number S0161
    Date submission received 2009-03-10
    Status Complete
    Recommendation

    Submission status report

  272. Rasagiline mesylate

    Brand name Azilect
    Manufacturer Teva Neurosciences
    Indication(s) Parkinson's disease
    Submission type Initial
    Project Number S0073
    Date submission received 2006-09-01
    Status Complete
    Date recommendation issued 2007-03-28
    Recommendation Do not list

    Submission status report

    Recommendation and reasons

  273. Rifaximin

    Brand name Zaxine
    Manufacturer Salix Pharmaceuticals Inc.
    Indication(s) Encephalopathy, Hepatic
    Submission type Initial
    Project Number SR0388
    Date submission received 2014-08-05
    Call for patient input 2014-07-09
    Patient input deadline 2014-08-28
    Status Active
    Recommendation

    Submission status report

  274. Rilpivirine

    Brand name Edurant
    Manufacturer Janssen Inc.
    Indication(s) HIV (treatment - naive adult)
    Submission type Initial
    Project Number S0243
    Date submission received 2011-07-29
    Call for patient input 2011-07-15
    Patient input deadline 2011-08-22
    Status Complete
    Date recommendation issued 2012-02-15
    Recommendation List

    Submission status report

    Recommendation and reasons

  275. Riociguat

    Brand name Adempas
    Manufacturer Bayer Inc.
    Indication(s) Pulmonary hypertension, chronic thromboembolic
    Submission type Initial
    Project Number SR0353
    Date submission received 2013-09-30
    Call for patient input 2013-09-12
    Patient input deadline 2013-10-22
    Status Active
    Date recommendation issued 2014-07-17
    Recommendation List with clinical criteria and/or conditions

    Submission status report

    Recommendation and reasons

  276. Rituximab

    Brand name Rituxan
    Manufacturer Hoffman-La Roche Ltd.
    Indication(s) Granulomatosis with Polyangiitis (GPA) and Microscopic Polyangiitis (MPA), remission induction (adults)
    Submission type New Indication
    Project Number SR0270
    Date submission received 2012-02-24
    Call for patient input 2012-02-24
    Patient input deadline 2012-03-16
    Status Complete
    Date recommendation issued 2012-08-16
    Recommendation List with criteria/condition

    Submission status report

    Recommendation and reasons

  277. Rituximab

    Brand name Rituxan
    Manufacturer Hoffmann-La Roche Limited
    Indication(s) Arthritis, Rheumatoid
    Submission type Initial
    Project Number S0068
    Date submission received 2006-06-26
    Status Complete
    Date recommendation issued 2007-02-14
    Recommendation List with criteria/condition

    Submission status report

    Recommendation and reasons

  278. Rivaroxaban

    Brand name Xarelto
    Manufacturer Bayer Inc.
    Indication(s) Thromboembolic events (venous), pulmonary embolism
    Submission type Initial
    Project Number SR0327
    Date submission received 2013-05-06
    Call for patient input 2013-04-05
    Patient input deadline 2013-05-27
    Status Active
    Date recommendation issued 2014-03-26
    Recommendation List with clinical criteria and/or conditions

    Submission status report

    Recommendation and reasons

  279. Rivaroxaban

    Brand name Xarelto
    Manufacturer Bayer Inc.
    Indication(s) stroke prevention in patients with atrial fibrillation.
    Submission type Request for Advice
    Project Number SF0321-00
    Date submission received 2013-03-18
    Status Complete
    Date recommendation issued 2013-07-18
    Recommendation List with criteria/condition

    Submission status report

    Recommendation and reasons

  280. Rivaroxaban

    Brand name Xarelto
    Manufacturer Bayer Inc.
    Indication(s) Deep-Vein Thrombosis (treatment), without Symptomatic Pulmonary Embolism
    Submission type Request for Advice
    Project Number SF0295
    Date submission received 2012-10-27
    Status Complete
    Recommendation

    Submission status report

    Record of Advice

  281. Rivaroxaban

    Brand name Xarelto
    Manufacturer Bayer Inc.
    Indication(s) Deep-Vein Thrombosis (treatment), without Symptomatic Pulmonary Embolism
    Submission type New Indication
    Project Number SR0271
    Date submission received 2012-02-27
    Call for patient input 2012-02-16
    Patient input deadline 2012-03-20
    Status Complete
    Date recommendation issued 2012-08-16
    Recommendation List with criteria/condition

    Submission status report

    Recommendation and reasons

  282. Rivaroxaban

    Brand name Xarelto
    Manufacturer Bayer Inc.
    Indication(s) Atrial fibrillation, stroke prevention
    Submission type Pre-NOC
    Project Number S0257
    Date submission received 2011-10-21
    Call for patient input 2011-10-18
    Patient input deadline 2011-11-09
    Status Complete
    Date recommendation issued 2012-04-19
    Recommendation List with criteria/condition

    Submission status report

    Recommendation and reasons

  283. Rivaroxaban

    Brand name Xarelto
    Manufacturer Bayer Inc.
    Indication(s) Thromboembolism (venous) prevention
    Submission type Request for Advice
    Project Number S0239
    Date submission received 2011-06-24
    Status Complete
    Recommendation

    Submission status report

  284. Rivaroxaban

    Brand name Xarelto
    Manufacturer Bayer Inc.
    Indication(s) Thromboembolism (venous), prevention
    Submission type Initial
    Project Number S0134
    Date submission received 2008-05-07
    Status Complete
    Date recommendation issued 2008-12-17
    Recommendation List with criteria/condition

    Submission status report

    Recommendation and reasons

  285. Rivastigmine

    Brand name Exelon Patch
    Manufacturer Novartis Pharmaceuticals Canada Inc.
    Indication(s) Dementia (Alzheimer's type)
    Submission type Initial
    Project Number S0123
    Date submission received 2007-12-21
    Status Complete
    Date recommendation issued 2008-07-23
    Recommendation Do not list

    Submission status report

    Recommendation and reasons

  286. Roflumilast

    Brand name Daxas
    Manufacturer Nycomed Canada Inc.
    Indication(s) Chronic obstructive pulmonary disease (COPD)
    Submission type Initial
    Project Number S0218
    Date submission received 2010-11-30
    Call for patient input 2010-11-18
    Patient input deadline 2011-01-24
    Status Complete
    Date recommendation issued 2011-07-27
    Recommendation Do not list
    Plain language recommendation Plain language recommendation

    Submission status report

    Recommendation and reasons

  287. Romiplostim

    Brand name Nplate
    Manufacturer Amgen Canada Inc.
    Indication(s) Chronic immune (idiopathic) thrombocytopenic purpura (ITP)
    Submission type Initial
    Project Number S0179
    Date submission received 2009-09-29
    Status Complete
    Date recommendation issued 2010-05-27
    Recommendation Do not list

    Submission status report

    Recommendation and reasons

  288. Rotigotine

    Brand name Neupro
    Manufacturer UCB Canada Inc.
    Indication(s) Parkinson’s Disease
    Submission type Initial
    Project Number SR0344
    Date submission received 2013-07-31
    Call for patient input 2013-07-30
    Patient input deadline 2013-08-22
    Status Active
    Date recommendation issued 2014-05-28
    Recommendation Do not list

    Submission status report

    Recommendation and reasons

  289. Rufinamide

    Brand name Banzel
    Manufacturer Eisai Limited
    Indication(s) Lennox-Gastaut syndrome; adjunctive treatment of seizures
    Submission type Initial
    Project Number S0252
    Date submission received 2011-09-20
    Call for patient input 2011-09-07
    Patient input deadline 2011-10-13
    Status Complete
    Date recommendation issued 2012-03-15
    Recommendation List with criteria/condition

    Submission status report

    Recommendation and reasons

  290. Sapropterin dihydrochloride

    Brand name Kuvan
    Manufacturer BioMarin Pharmaceutical Canada Inc.
    Indication(s) Phenylketonuria (PKU).
    Submission type Request for Advice
    Project Number S0236
    Date submission received 2011-06-01
    Status Complete
    Date advice issued 2011-10-26
    Recommendation

    Submission status report

  291. Sapropterin dihydrochloride

    Brand name Kuvan
    Manufacturer BioMarin Pharmaceutical Canada Inc.
    Indication(s) Phenylketonuria (PKU).
    Submission type Initial
    Project Number S0205
    Date submission received 2010-07-08
    Call for patient input 2010-07-05
    Patient input deadline 2010-07-29
    Status Complete
    Date recommendation issued 2011-01-26
    Recommendation Do not list
    Plain language recommendation Plain language recommendation

    Submission status report

    Recommendation and reasons

  292. Saxagliptin

    Brand name Onglyza
    Manufacturer Bristol-Myers Squibb / AstraZeneca Canada Inc.
    Indication(s) Diabetes mellitus (Type 2)
    Submission type Pre-NOC
    Project Number SR0329
    Date submission received 2013-05-09
    Call for patient input 2013-05-09
    Patient input deadline 2013-05-31
    Status Complete
    Date recommendation issued 2013-11-15
    Recommendation List with clinical criteria and/or conditions

    Submission status report

    Clinical Report

    Pharmacoeconomic Report

    Recommendation and reasons

  293. Saxagliptin

    Brand name Onglyza
    Manufacturer Bristol-Myers Squibb / AstraZeneca Canada Inc.
    Indication(s) Diabetes mellitus (Type 2)
    Submission type Resubmission #1
    Project Number SR0280
    Date submission received 2012-05-28
    Call for patient input 2012-05-28
    Patient input deadline 2012-06-18
    Status Withdrawn
    Recommendation

    Submission status report

  294. Saxagliptin

    Brand name Onglyza
    Manufacturer Bristol-Myers Squibb Canada
    Indication(s) Diabetes mellitus (Type 2)
    Submission type Initial
    Project Number S0185
    Date submission received 2009-11-09
    Status Complete
    Date recommendation issued 2010-06-17
    Recommendation Do not list

    Submission status report

    Recommendation and reasons

  295. Saxagliptin + metformin

    Brand name Komboglyze
    Manufacturer AstraZeneca Canada Inc.
    Indication(s) Diabetes Mellitus, Type 2
    Submission type Initial
    Project Number SR0348
    Date submission received 2013-08-23
    Call for patient input 2013-08-26
    Patient input deadline 2013-09-17
    Status Active
    Date recommendation issued 2014-06-20
    Recommendation List with clinical criteria and/or conditions

    Submission status report

    Recommendation and reasons

  296. Saxagliptin + metformin

    Brand name Komboglyze
    Manufacturer Bristol-Myers Squibb / AstraZeneca Canada Inc.
    Indication(s) Diabetes Mellitus, Type 2
    Submission type Initial
    Project Number SR0336
    Date submission received 2013-06-06
    Call for patient input 2013-06-13
    Patient input deadline 2013-07-05
    Status Withdrawn
    Recommendation

    Submission status report

  297. Secukinumab

    Brand name TBC
    Manufacturer Novartis Pharmaceuticals Canada Inc.
    Indication(s) Psoriasis, moderate to severe plaque
    Submission type Initial
    Project Number SR0407-000
    Date submission received 2014-12-08
    Call for patient input 2014-11-05
    Patient input deadline 2014-12-24
    Status Received
    Recommendation

    Submit Patient Input


    Submission status report

  298. Sildenafil citrate

    Brand name Revatio
    Manufacturer Pfizer Canada Inc.
    Indication(s) Pulmonary arterial hypertension (WHO class II and III)
    Submission type Initial
    Project Number S0076
    Date submission received 2006-09-20
    Status Complete
    Date recommendation issued 2007-02-14
    Recommendation List in a similar manner

    Submission status report

    Recommendation and reasons

  299. Silodosin

    Brand name RAPAFLO
    Manufacturer Watson Pharma Company
    Indication(s) Prostatic Hyperplasia, benign
    Submission type Initial
    Project Number S0261
    Date submission received 2011-10-25
    Call for patient input 2011-10-13
    Patient input deadline 2011-11-17
    Status Complete
    Date recommendation issued 2012-04-19
    Recommendation Do not list

    Submission status report

    Recommendation and reasons

  300. Simeprevir

    Brand name Galexos
    Manufacturer Janssen Inc.
    Indication(s) Hepatitis C, chronic
    Submission type Pre-NOC
    Project Number SR0347
    Date submission received 2013-08-22
    Call for patient input 2013-08-22
    Patient input deadline 2013-09-13
    Status Active
    Date recommendation issued 2014-06-18
    Recommendation List with clinical criteria and/or conditions

    Submission status report

    Recommendation and reasons

  301. Sitagliptin phosphate

    Brand name Januvia
    Manufacturer Merck Frosst Canada Ltd.
    Indication(s) Diabetes mellitus (Type 2)
    Submission type Resubmission #1
    Project Number S0181
    Date submission received 2009-10-29
    Status Complete
    Date recommendation issued 2010-06-23
    Recommendation List with criteria/condition

    Submission status report

    Recommendation and reasons

  302. Sitagliptin phosphate

    Brand name Januvia
    Manufacturer Merck Frosst Canada Ltd.
    Indication(s) Diabetes mellitus (Type 2)
    Submission type Initial
    Project Number S0122
    Date submission received 2007-12-20
    Status Complete
    Date recommendation issued 2008-06-18
    Recommendation Do not list
    Plain language recommendation Plain language recommendation
    Summary of CEDAC Discussion Summary of CEDAC Discussion
    Overview of CDR reports Overview of CDR reports

    Submission status report

    Recommendation and reasons

  303. Sitagliptin phosphate monohydrate / metformin hydrochloride

    Brand name Janumet
    Manufacturer Merck Frosst Canada Ltd.
    Indication(s) Diabetes mellitus (Type 2)
    Submission type Initial
    Project Number S0182
    Date submission received 2009-11-04
    Status Complete
    Date recommendation issued 2010-06-23
    Recommendation List with criteria/condition

    Submission status report

    Recommendation and reasons

  304. Sitaxsentan sodium

    Brand name Thelin
    Manufacturer Encysive Canada Inc.
    Indication(s) Pulmonary arterial hypertension (WHO class II and III)
    Submission type Resubmission #1
    Project Number S0132
    Date submission received 2008-05-05
    Status Complete
    Date recommendation issued 2009-01-28
    Recommendation Do not list

    Submission status report

    Recommendation and reasons

  305. Sitaxsentan sodium

    Brand name Thelin
    Manufacturer Encysive Canada Inc.
    Indication(s) Pulmonary arterial hypertension (WHO class II and III)
    Submission type Initial
    Project Number S0099
    Date submission received 2007-06-22
    Status Complete
    Date recommendation issued 2008-01-30
    Recommendation Do not list

    Submission status report

    Recommendation and reasons

  306. Sodium oxybate

    Brand name Xyrem
    Manufacturer Valeant Canada Ltd.
    Indication(s) Narcolepsy
    Submission type Resubmission #1
    Project Number S0141
    Date submission received 2008-07-09
    Status Complete
    Date recommendation issued 2009-01-28
    Recommendation Do not list

    Submission status report

    Recommendation and reasons

  307. Sodium oxybate

    Brand name Xyrem
    Manufacturer Valeant Canada Ltd.
    Indication(s) Narcolepsy
    Submission type Initial
    Project Number S0107
    Date submission received 2007-08-29
    Status Withdrawn
    Recommendation

    Submission status report

  308. Sofosbuvir

    Brand name Sovaldi
    Manufacturer Gilead Sciences Canada Inc.
    Indication(s) Hepatitis C, chronic
    Submission type Pre-NOC
    Project Number SR0356
    Date submission received 2013-10-01
    Call for patient input 2013-10-01
    Patient input deadline 2013-10-23
    Status Complete
    Date recommendation issued 2014-08-20
    Recommendation List with clinical criteria and/or conditions

    Submission status report

    Clinical Report

    Pharmacoeconomic Report

    Recommendation and reasons

  309. Solifenacin succinate

    Brand name Vesicare
    Manufacturer Astellas Pharma Canada Inc.
    Indication(s) Bladder, overactive
    Submission type Resubmission #1
    Project Number S0155
    Date submission received 2009-01-05
    Status Complete
    Date recommendation issued 2009-06-17
    Recommendation List with criteria/condition

    Submission status report

    Recommendation and reasons

  310. Solifenacin succinate

    Brand name Vesicare
    Manufacturer Astellas Pharma Canada Inc.
    Indication(s) Bladder, overactive
    Submission type Initial
    Project Number S0070
    Date submission received 2006-07-24
    Status Complete
    Date recommendation issued 2007-01-24
    Recommendation Do not list

    Submission status report

    Recommendation and reasons

  311. Somatropin

    Brand name Genotropin
    Manufacturer Pfizer Canada Inc.
    Indication(s) Growth hormone deficiency, adult
    Submission type Initial
    Project Number SR0332
    Date submission received 2013-05-27
    Call for patient input 2013-05-28
    Patient input deadline 2013-06-18
    Status Complete
    Date recommendation issued 2013-12-20
    Recommendation List with clinical criteria and/or conditions

    Submission status report

    Clinical Report

    Pharmacoeconomic Report

    Recommendation and reasons

  312. Somatropin

    Brand name Genotropin
    Manufacturer Pfizer Canada Inc.
    Indication(s) Growth hormone deficiency, pediatric
    Submission type Initial
    Project Number SR0333
    Date submission received 2013-05-27
    Call for patient input 2013-05-28
    Patient input deadline 2013-06-18
    Status Complete
    Date recommendation issued 2013-12-20
    Recommendation List with clinical criteria and/or conditions

    Submission status report

    Clinical Report

    Pharmacoeconomic Report

    Recommendation and reasons

  313. Somatropin

    Brand name Genotropin
    Manufacturer Pfizer Canada Inc.
    Indication(s) Turner Syndrome
    Submission type Initial
    Project Number SR0334
    Date submission received 2013-05-27
    Call for patient input 2013-05-28
    Patient input deadline 2013-06-18
    Status Complete
    Date recommendation issued 2013-12-20
    Recommendation List with clinical criteria and/or conditions

    Submission status report

    Clinical Report

    Pharmacoeconomic Report

    Recommendation and reasons

  314. Somatropin (rDNA origin)

    Brand name Omnitrope
    Manufacturer Sandoz Canada Inc.
    Indication(s) Growth hormone deficiency in children and adults
    Submission type Initial
    Project Number S0167
    Date submission received 2009-06-12
    Status Complete
    Date advice issued 2009-12-16
    Recommendation

    Submission status report

    Advice - SEB

  315. Sorafenib tablets

    Brand name Nexavar
    Manufacturer Bayer Inc.
    Indication(s) Cancer, Renal cell carcinoma
    Submission type Initial
    Project Number S0071
    Date submission received 2006-07-31
    Status Complete
    Date recommendation issued 2007-02-28
    Recommendation Do not list

    Submission status report

    Recommendation and reasons

  316. Stiripentol

    Brand name Diacomit
    Manufacturer Biocodex
    Indication(s) Dravet Syndrome
    Submission type Initial
    Project Number SR0360-000
    Date submission received 2013-10-30
    Call for patient input 2013-09-27
    Patient input deadline 2013-11-18
    Status Active
    Date recommendation issued 2014-10-16
    Recommendation List with clinical criteria and/or conditions

    Submission status report

    Recommendation and reasons

  317. Sunitinib

    Brand name Sutent
    Manufacturer Pfizer Canada Inc.
    Indication(s) Gastrointestinal stromal tumour (GIST)
    Submission type Initial
    Project Number S0069
    Date submission received 2006-07-20
    Status Complete
    Date recommendation issued 2007-03-28
    Recommendation List with criteria/condition

    Submission status report

    Recommendation and reasons

  318. Sunitinib malate

    Brand name Sutent
    Manufacturer Pfizer Canada Inc.
    Indication(s) Cancer, Metastatic renal cell carcinoma
    Submission type Resubmission #1
    Project Number S0077
    Date submission received 2006-09-20
    Status Complete
    Date recommendation issued 2007-04-26
    Recommendation Do not list

    Submission status report

    Recommendation and reasons

  319. Tadalafil

    Brand name Adcirca
    Manufacturer Eli Lilly Canada Inc.
    Indication(s) Pulmonary arterial hypertension
    Submission type Initial
    Project Number S0197
    Date submission received 2010-02-05
    Status Complete
    Date recommendation issued 2010-07-15
    Recommendation List with criteria/condition

    Submission status report

    Recommendation and reasons

  320. Taliglucerase alfa

    Brand name Elelyso
    Manufacturer Pfizer Canada Inc.
    Indication(s) Gaucher disease
    Submission type Initial
    Project Number SR0390
    Date submission received 2014-08-15
    Call for patient input 2014-07-24
    Patient input deadline 2014-09-15
    Status Received
    Recommendation

    Submission status report

  321. Tapentadol

    Brand name Nucynta CR
    Manufacturer Janssen Inc.
    Indication(s) Pain, moderate to moderately severe
    Submission type Initial
    Project Number S0224
    Date submission received 2011-02-01
    Call for patient input 2011-01-20
    Patient input deadline 2011-02-24
    Status Complete
    Date recommendation issued 2011-09-28
    Recommendation Do not list
    Plain language recommendation Plain language recommendation

    Submission status report

    Recommendation and reasons

  322. Tedizolid phosphate

    Brand name Sivextro
    Manufacturer Cubist Pharmaceuticals Canada, Inc.
    Indication(s) Acute bacterial skin and skin structure infections
    Submission type Initial
    Project Number TBC
    Date submission received 2015-01-09 (Tentative)
    Call for patient input 2014-12-10
    Patient input deadline 2015-02-05
    Status Pending
    Recommendation

    Submit Patient Input


  323. Telaprevir

    Brand name Incivek
    Manufacturer Vertex Pharmaceuticals Canada Inc.
    Indication(s) Hepatitis C infection, chronic
    Submission type Request for Advice
    Project Number SF0311
    Date submission received 2013-02-19
    Status Complete
    Date recommendation issued 2013-06-13
    Recommendation List with clinical criteria and/or conditions

    Submission status report

    Recommendation and reasons

  324. Telaprevir

    Brand name Incivek
    Manufacturer Vertex Pharmaceuticals Canada Inc.
    Indication(s) Hepatitis C, chronic
    Submission type Request for Advice
    Project Number SF0305-000
    Date submission received 2013-01-02
    Status Complete
    Date recommendation issued 2013-06-13
    Recommendation List with clinical criteria and/or conditions

    Submission status report

    Recommendation and reasons

  325. Telaprevir

    Brand name Incivek
    Manufacturer Vertex Pharmaceuticals Inc.
    Indication(s) Hepatitis C infection (genotype 1), Chronic
    Submission type Initial
    Project Number S0249
    Date submission received 2011-08-23
    Call for patient input 2011-08-16
    Patient input deadline 2011-09-14
    Status Complete
    Date recommendation issued 2012-02-15
    Recommendation List with criteria/condition

    Submission status report

    Recommendation and reasons

  326. Telbivudine

    Brand name Sebivo
    Manufacturer Novartis Pharmaceuticals Canada Inc.
    Indication(s) Hepatitis B (chronic)
    Submission type Initial
    Project Number S0088
    Date submission received 2006-12-04
    Status Complete
    Date recommendation issued 2007-09-26
    Recommendation Do not list

    Submission status report

    Recommendation and reasons

  327. Telmisartan / Amlodipine

    Brand name Twynsta
    Manufacturer Boehringer Ingelheim (Canada) Ltd
    Indication(s) Hypertension, Essential
    Submission type Pre-NOC
    Project Number S0207
    Date submission received 2010-07-09
    Call for patient input 2010-07-09
    Patient input deadline 2010-07-30
    Status Rejected
    Recommendation

    Submission status report

  328. Telmisartan / Amlodipine

    Brand name Twynsta
    Manufacturer Boehringer Ingelheim Canada
    Indication(s) Hypertension, Essential
    Submission type Initial
    Project Number S0245
    Date submission received 2011-08-23
    Call for patient input 2011-08-09
    Patient input deadline 2011-09-14
    Status Complete
    Date recommendation issued 2011-12-16
    Recommendation List
    Plain language recommendation Plain language recommendation

    Submission status report

    Recommendation and reasons

  329. Tenofovir disoproxil fumarate

    Brand name Viread
    Manufacturer Gilead Sciences Canada Inc.
    Indication(s) Hepatitis B (chronic)
    Submission type New Indication
    Project Number S0148
    Date submission received 2008-10-02
    Status Complete
    Date recommendation issued 2009-03-18
    Recommendation List with criteria/condition

    Submission status report

    Recommendation and reasons

  330. Tenofovir disoproxil fumarate

    Brand name Viread
    Manufacturer Gilead Sciences Canada Inc.
    Indication(s) HIV infection
    Submission type Request for Advice
    Project Number S0139
    Date submission received 2008-07-07
    Status Complete
    Recommendation

    Submission status report

  331. Tenofovir disoproxil fumarate

    Brand name Viread
    Manufacturer Gilead Sciences Canada Inc.
    Indication(s) HIV infection
    Submission type Resubmission #1
    Project Number S0040
    Date submission received 2005-08-11
    Status Complete
    Date recommendation issued 2006-03-15
    Recommendation List with criteria/condition

    Submission status report

    Recommendation and reasons

  332. Tenofovir disoproxil fumarate

    Brand name Viread
    Manufacturer Gilead Sciences Canada Inc.
    Indication(s) HIV infection
    Submission type Initial
    Project Number S0008
    Date submission received 2004-02-23
    Status Complete
    Date recommendation issued 2004-08-25
    Recommendation Do not list

    Submission status report

    Recommendation and reasons

  333. Teriflunomide

    Brand name Aubagio
    Manufacturer Genzyme Canada, a Division of Sanofi Aventis Canada Inc.
    Indication(s) Multiple Sclerosis, relapsing
    Submission type Pre-NOC
    Project Number SR0350
    Date submission received 2013-08-28
    Call for patient input 2013-08-28
    Patient input deadline 2013-09-20
    Status Complete
    Date recommendation issued 2014-06-18
    Recommendation Do not list at the submitted price

    Submission status report

    Clinical Report

    Pharmacoeconomic Report

    Recommendation and reasons

  334. Teriparatide (rDNA origin) injection

    Brand name Forteo
    Manufacturer Eli Lilly Canada Inc.
    Indication(s) Osteoporosis (in women), Severe
    Submission type ACP Submission
    Project Number S0180
    Date submission received 2009-10-23
    Status Complete
    Date recommendation issued 2010-03-17
    Recommendation Do not list

    Submission status report

    Recommendation and reasons

  335. Teriparatide (rDNA origin) injection

    Brand name Forteo
    Manufacturer Eli Lilly Canada Inc.
    Indication(s) Osteoporosis
    Submission type Resubmission #3
    Project Number S0169
    Date submission received 2009-06-12
    Status Withdrawn
    Recommendation

    Submission status report

  336. Teriparatide (rDNA origin) injection

    Brand name Forteo
    Manufacturer Eli Lilly Canada Inc.
    Indication(s) Osteoporosis, glucocorticoid induced
    Submission type New Indication
    Project Number S0152
    Date submission received 2008-12-18
    Status Complete
    Date recommendation issued 2009-07-22
    Recommendation Do not list

    Submission status report

    Recommendation and reasons

  337. Teriparatide (rDNA origin) injection

    Brand name Forteo
    Manufacturer Eli Lilly Canada Inc.
    Indication(s) Osteoporosis
    Submission type Resubmission #2
    Project Number S0157
    Date submission received 2008-12-18
    Status Withdrawn
    Recommendation

    Submission status report

  338. Teriparatide (rDNA origin) injection

    Brand name Forteo
    Manufacturer Eli Lilly Canada Inc.
    Indication(s) Osteoporosis
    Submission type Resubmission #1
    Project Number S0065
    Date submission received 2006-05-29
    Status Withdrawn
    Recommendation

    Submission status report

  339. Teriparatide (rDNA origin) injection

    Brand name Forteo
    Manufacturer Eli Lilly Canada Inc.
    Indication(s) Osteoporosis
    Submission type Initial
    Project Number S0015
    Date submission received 2004-06-08
    Status Complete
    Date recommendation issued 2004-12-22
    Recommendation Do not list

    Submission status report

    Recommendation and reasons

  340. Ticagrelor

    Brand name Brilinta
    Manufacturer AstraZeneca Canada Inc
    Indication(s) Thrombotic events in Acute Coronary Syndromes, Prevention
    Submission type Initial
    Project Number S0234
    Date submission received 2011-06-01
    Call for patient input 2011-05-17
    Patient input deadline 2011-06-22
    Status Complete
    Date recommendation issued 2011-12-16
    Recommendation Do not list
    Plain language recommendation Plain language recommendation

    Submission status report

    Recommendation and reasons

  341. Ticagrelor

    Brand name Brilinta
    Manufacturer AstraZeneca Canada Inc
    Indication(s) Acute Coronary Syndromes (ACS)
    Submission type Pre-NOC - Initial
    Project Number S0203
    Date submission received 2010-06-08
    Call for patient input 2010-06-08
    Patient input deadline 2010-06-30
    Status Stopped
    Recommendation

    Submission status report

  342. Tiotropium bromide

    Brand name Spiriva Respimat
    Manufacturer Boehringer Ingelheim (Canada) Ltd.
    Indication(s) Chronic Obstructive Pulmonary Disease (COPD)
    Submission type Initial
    Project Number TBD
    Date submission received 2014-12-23 (Tentative)
    Call for patient input 2014-11-27
    Patient input deadline 2015-01-23
    Status Pending
    Recommendation

    Submit Patient Input


  343. Tipranavir

    Brand name Aptivus
    Manufacturer Boehringer Ingelheim (Canada) Inc.
    Indication(s) HIV infection
    Submission type Initial
    Project Number S0047
    Date submission received 2005-12-15
    Status Complete
    Date recommendation issued 2006-05-17
    Recommendation List with criteria/condition

    Submission status report

    Recommendation and reasons

  344. Tocilizumab

    Brand name Actemra
    Manufacturer Hoffmann-La Roche Limited
    Indication(s) Arthritis, Rheumatoid
    Submission type Pre-NOC
    Project Number SR0374-000
    Date submission received 2014-03-03
    Call for patient input 2014-07-09
    Patient input deadline 2014-08-28
    Status Active
    Recommendation

    Submission status report

  345. Tocilizumab

    Brand name Actemra
    Manufacturer Hoffmann-La Roche Limited
    Indication(s) Polyarticular juvenile idiopathic arthritis
    Submission type New Indication
    Project Number SR0343
    Date submission received 2013-07-29
    Call for patient input 2013-07-08
    Patient input deadline 2013-08-12
    Status Complete
    Date recommendation issued 2014-03-19
    Recommendation List with clinical criteria and/or conditions

    Submission status report

    Clinical Report

    Pharmacoeconomic Report

    Recommendation and reasons

  346. Tocilizumab

    Brand name Actemra
    Manufacturer Hoffman-La Roche Ltd.
    Indication(s) Arthritis, juvenile idiopathic
    Submission type New Indication
    Project Number S0267
    Date submission received 2012-01-30
    Call for patient input 2012-01-30
    Patient input deadline 2012-02-17
    Status Complete
    Date recommendation issued 2012-07-19
    Recommendation List with criteria/condition

    Submission status report

    Recommendation and reasons

  347. Tocilizumab

    Brand name Actemra
    Manufacturer Hoffmann-La Roche Limited
    Indication(s) Arthritis, Rheumatoid
    Submission type Initial
    Project Number S0201
    Date submission received 2010-05-27
    Call for patient input 2010-05-21
    Patient input deadline 2010-06-17
    Status Complete
    Date recommendation issued 2010-11-17
    Recommendation List with criteria/condition
    Plain language recommendation Plain language recommendation

    Submission status report

    Recommendation and reasons

  348. Tofacitinib

    Brand name Xeljanz
    Manufacturer Pfizer Canada Inc.
    Indication(s) Arthritis, Rheumatoid
    Submission type Initial
    Project Number SR0380-000
    Date submission received 2014-05-05
    Call for patient input 2014-07-09
    Patient input deadline 2014-08-28
    Status Active
    Recommendation

    Submission status report

  349. Tolvaptan

    Brand name Samsca
    Manufacturer Otsuka Canada Pharmaceutical Inc.
    Indication(s) Hyponatremia, non-hypovolemic
    Submission type Initial
    Project Number SR0283
    Date submission received 2012-07-03
    Call for patient input 2012-07-03
    Patient input deadline 2012-07-24
    Status Complete
    Date recommendation issued 2013-02-13
    Recommendation Do not list

    Submission status report

    Recommendation and reasons

  350. Tramadol hydrochloride

    Brand name Tridural
    Manufacturer Labopharm Inc.
    Indication(s) Pain
    Submission type Initial
    Project Number S0117
    Date submission received 2007-11-29
    Status Complete
    Date recommendation issued 2008-04-17
    Recommendation Do not list

    Submission status report

    Recommendation and reasons

  351. Tramadol hydrochloride

    Brand name Ralivia
    Manufacturer Biovail Pharmaceuticals Canada
    Indication(s) Pain
    Submission type Initial
    Project Number S0110
    Date submission received 2007-10-29
    Status Complete
    Date recommendation issued 2008-06-25
    Recommendation Do not list

    Submission status report

    Recommendation and reasons

  352. Tramadol hydrochloride

    Brand name Zytram XL
    Manufacturer Purdue Pharma
    Indication(s) Pain, acute
    Submission type Resubmission #1
    Project Number S0093
    Date submission received 2007-03-15
    Status Complete
    Date recommendation issued 2007-09-26
    Recommendation Do not list

    Submission status report

    Recommendation and reasons

  353. Tramadol hydrochloride

    Brand name Zytram XL
    Manufacturer Purdue Pharma
    Indication(s) Pain, acute
    Submission type Initial
    Project Number S0086
    Date submission received 2006-11-03
    Status Withdrawn
    Recommendation

    Submission status report

  354. Tramadol hydrochloride / acetaminophen

    Brand name Tramacet
    Manufacturer Janssen-Ortho Inc.
    Indication(s) Acute pain
    Submission type Initial
    Project Number S0079
    Date submission received 2006-10-02
    Status Complete
    Date recommendation issued 2007-05-17
    Recommendation Do not list

    Submission status report

    Recommendation and reasons

  355. Travoprost and timolol maleate

    Brand name DuoTrav
    Manufacturer Alcon Canada Inc.
    Indication(s) Glaucoma
    Submission type Initial
    Project Number S0057
    Date submission received 2006-03-24
    Status Complete
    Date recommendation issued 2006-08-24
    Recommendation List with criteria/condition

    Submission status report

    Recommendation and reasons

  356. Treprostinil sodium

    Brand name Remodulin
    Manufacturer Northern Therapeutics Inc.
    Indication(s) Pulmonary arterial hypertension (NYHA Class III and IV patients)
    Submission type Resubmission #1
    Project Number S0052
    Date submission received 2006-02-24
    Status Complete
    Date recommendation issued 2006-07-20
    Recommendation List with criteria/condition

    Submission status report

    Recommendation and reasons

  357. Treprostinil sodium

    Brand name Remodulin
    Manufacturer Northern Therapeutics Inc.
    Indication(s) Pulmonary arterial hypertension (NYHA Class III and IV patients)
    Submission type Initial
    Project Number S0011
    Date submission received 2004-07-14
    Status Complete
    Date recommendation issued 2004-11-17
    Recommendation Do not list

    Submission status report

    Recommendation and reasons

  358. Triptorelin pamoate

    Brand name Trelstar
    Manufacturer Watson Laboratories Inc.
    Indication(s) Cancer, prostate
    Submission type Initial
    Project Number S0051
    Date submission received 2006-02-27
    Status Complete
    Date recommendation issued 2006-07-20
    Recommendation List in a similar manner to other drugs in class

    Submission status report

    Recommendation and reasons

  359. Trospium chloride

    Brand name Trosec
    Manufacturer Oryx Pharmaceuticals Inc.
    Indication(s) Bladder, overactive
    Submission type Initial
    Project Number S0055
    Date submission received 2006-03-24
    Status Complete
    Date recommendation issued 2006-08-24
    Recommendation List with criteria/condition

    Submission status report

    Recommendation and reasons

  360. Ulipristal acetate

    Brand name Fibristal
    Manufacturer Actavis Specialty Pharmaceuticals Co.
    Indication(s) Uterine fibroids (signs and symptoms)
    Submission type Pre-NOC
    Project Number SR0326
    Date submission received 2013-04-17
    Call for patient input 2013-04-15
    Patient input deadline 2013-05-09
    Status Complete
    Date recommendation issued 2013-11-15
    Recommendation List with clinical criteria and/or conditions

    Submission status report

    Clinical Report

    Pharmacoeconomic Report

    Recommendation and reasons

  361. Umeclidinium / vilanterol

    Brand name Anoro Ellipta
    Manufacturer GlaxoSmithKline Inc.
    Indication(s) Chronic Obstructive Pulmonary Disease
    Submission type Initial
    Project Number SR0371-000
    Date submission received 2014-02-26
    Call for patient input 2014-07-09
    Patient input deadline 2014-08-28
    Status Active
    Recommendation

    Submission status report

  362. Ustekinumab

    Brand name Stelara
    Manufacturer Janssen Inc.
    Indication(s) Arthritis, Psoriatic
    Submission type Pre-NOC
    Project Number SR0359-000
    Date submission received 2013-10-30
    Call for patient input 2014-02-10
    Patient input deadline 2014-04-01
    Status Active
    Date recommendation issued 2014-10-20
    Recommendation Do not list at the submitted price

    Submission status report

    Recommendation and reasons

  363. Ustekinumab

    Brand name Stelara
    Manufacturer Janssen-Ortho Inc.
    Indication(s) Psoriasis
    Submission type Initial
    Project Number S0156
    Date submission received 2009-01-07
    Status Complete
    Date recommendation issued 2009-06-17
    Recommendation List with criteria/condition

    Submission status report

    Recommendation and reasons

  364. Varenicline tartrate

    Brand name Champix
    Manufacturer Pfizer Canada Inc.
    Indication(s) Smoking-cessation
    Submission type Initial
    Project Number S0094
    Date submission received 2007-03-21
    Status Complete
    Date recommendation issued 2007-08-16
    Recommendation List with criteria/condition

    Submission status report

    Recommendation and reasons

  365. Velaglucerase alfa

    Brand name VPRIV
    Manufacturer Shire Human Genetic Therapies
    Indication(s) Gaucher Disease
    Submission type Initial
    Project Number S0215
    Date submission received 2010-10-28
    Call for patient input 2010-10-29
    Patient input deadline 2010-11-18
    Status Complete
    Date recommendation issued 2011-04-25
    Recommendation List with criteria/condition
    Plain language recommendation Plain language recommendation

    Submission status report

    Recommendation and reasons

  366. Voriconazole

    Brand name VFEND
    Manufacturer Pfizer Canada Inc.
    Indication(s) Candidemia
    Submission type Resubmission #2
    Project Number S0056
    Date submission received 2006-03-24
    Status Complete
    Date recommendation issued 2006-10-25
    Recommendation List with criteria/condition

    Submission status report

    Recommendation and reasons

  367. Voriconazole

    Brand name VFEND
    Manufacturer Pfizer Canada Inc.
    Indication(s) Aspergillosis, Invasive
    Submission type Resubmission #1
    Project Number S0023
    Date submission received 2004-10-25
    Status Complete
    Date recommendation issued 2005-04-14
    Recommendation List with criteria/condition

    Submission status report

    Recommendation and reasons

  368. Voriconazole

    Brand name VFEND
    Manufacturer Pfizer Canada Inc.
    Indication(s) Aspergillosis, Invasive
    Submission type Initial
    Project Number S0020
    Date submission received 2004-08-24
    Status Withdrawn
    Recommendation

    Submission status report

  369. Vortioxetine

    Brand name Trintellix
    Manufacturer Lundbeck Canada Inc.
    Indication(s) Depression, Major Depressive Disorder (MDD)
    Submission type Initial
    Project Number SR0402
    Date submission received 2014-10-31
    Call for patient input 2014-09-25
    Patient input deadline 2014-11-14
    Status Active
    Recommendation

    Submission status report

  370. Ziprasidone hydrochloride

    Brand name Zeldox
    Manufacturer Pfizer Canada Inc.
    Indication(s) Schizophrenia and related psychotic disorders
    Submission type Initial
    Project Number S0124
    Date submission received 2008-01-10
    Status Complete
    Date recommendation issued 2008-08-14
    Recommendation List with criteria/condition

    Submission status report

    Recommendation and reasons

  371. Zoledronic acid

    Brand name Aclasta
    Manufacturer Novartis Pharmaceuticals Canada Inc.
    Indication(s) Osteoporosis (postmenopausal women)
    Submission type Request for Advice
    Project Number S0242
    Date submission received 2011-07-20
    Status Complete
    Date recommendation issued 2011-11-16
    Recommendation List with criteria/condition
    Plain language recommendation Plain language recommendation

    Submission status report

    Recommendation and reasons

  372. Zoledronic acid

    Brand name Aclasta
    Manufacturer Novartis Pharmaceuticals Canada Inc.
    Indication(s) Osteoporosis, postmenopausal women
    Submission type Initial
    Project Number S0114
    Date submission received 2007-11-29
    Status Complete
    Date recommendation issued 2008-06-25
    Recommendation List with criteria/condition

    Submission status report

    Recommendation and reasons

  373. Zolpidem tartrate

    Brand name Sublinox
    Manufacturer Meda Valeant Pharma Canada Inc.
    Indication(s) Insomnia, short-term treatment
    Submission type Initial
    Project Number SR0314
    Date submission received 2013-03-07
    Call for patient input 2013-03-07
    Patient input deadline 2013-03-28
    Status Complete
    Date recommendation issued 2013-09-25
    Recommendation Do not list

    Submission status report

    Recommendation and reasons